



2024

Semi-annual JGL Group
Management Report



Purpose


We help people sense the world around them in a better, richer and more confident way.

Experience the scent of the Earth, see the world of possibilities, feel good in your skin!


Sense the life.

Mission

We improve the quality of life by taking care of your health.







JADRAN-GALENSKI LABORATORIJ d.d. (“JGL”, “Company” or “Parent Company”) accepts responsibility for the content of this Semi-annual Management Report of the JGL Group.

Given the belief and all discoveries and information available to JGL, information in this Report represents a complete and truthful presentation of assets and liabilities, losses and gains and the financial position of the JGL Group, and to the best knowledge of the Company, no fact has been left out that can affect the completeness and truthfulness of this report.

Individual numbers in the Report are rounded, so the numbers shown for the same type of information can differ and the sums may not be arithmetic aggregates. In this document, “EUR” stands for the euro, and “USD” for the American dollar.

Reference to the “previous period” relates to the period from 1 January 2023 to 30 June 2023, while the “current period” relates to the period from 1 January 2024 to 30 June 2024.

Rijeka, August 2024

Table of Contents

8	Introduction
10	Company Profile
14	Key Indicators
16	Sales Results
26	Areas and Activities
36	Structural Changes
38	Share Transactions and New Share Issue
40	Affiliated Companies
46	Financial Performance
54	Business Risks
60	Future Development
62	JGL Group Financial Statements
77	JGL d.d. Financial Statements
92	Chief Executive Officer's responsibilities

This version of the semi-annual report is a translation from the original, which was prepared in the Croatian language.

All possible care has been taken to ensure that the translation is an accurate representation of the original. However, in all matters of interpretation of information, views or opinions, the original language version of the annual report takes precedence over translation.

Introduction



Dear Stakeholders,

We ended the first half of 2024 with double-digit growth over the same period last year. JGL Group's total revenue amounts to EUR 127.6 million, and profit before tax EUR 20.1 million, which makes for a record breaking semi-annual result. When compared to the same period last year, this translates to an increase in total revenue of 22.5 percent. In the past 12 months, JGL Pharma's business revenues reached EUR 198.8 million. The EBITDA MAT stands at EUR 39.1 million, with a EBITDA MAT margin of 19.7 percent. For this result I would like to thank all the employees of our Group, as well as our numerous partners, customers and suppliers.

The vision that inspires and guides us can be summed up in the following: we want to be a leading international pharmaceutical company that develops and manufactures innovative pharmaceutical products in three therapeutic areas: cold and flu, ophthalmology, and dermatology. This requires our full technological and therapeutic focus and strategic competence, as well as the dedication and enthusiasm of our employees. Every step we take in the development, production, and sales segments is dedicated to fulfilling this vision.

The cold and flu segment has traditionally held the largest share of net sales. However, in recent years, we have worked hard to diversify and strengthen sales in other areas based on these strategic areas. I am delighted that our efforts have paid off, as demonstrated by the numbers: in the first half of 2024, sales in dermatology increased by an impressive 42 percent, and ophthalmology saw a 33 percent growth compared to

the same period last year. We are pleased with both the rate and depth of brands' growth, as well as the breath of market expansion.

Aligned with our vision, we are implementing specific steps to achieve our goals. We are consistently increasing our research and development investments to develop innovative products tailored to user needs. We have more than doubled our investment in R&D in the last three years alone.

By continuously investing in production capacities and technologies, such as the significant investment in the INTEGRA project completed in September 2023, we ensure the reliable and efficient production of our pharmaceutical forms. JGL's commitment to quality and innovation ensures we remain a leader in our areas of operation, offering only the best products for the health and well-being of our customers.

In achieving this, we rely on our internal expertise and infrastructure, combined with partnerships with specialised research organizations, domestic and international experts, and the academic community in Croatia and elsewhere.

As our financial indicators grow, our team is also increasing in size. Thirty years ago, the Company had about twenty employees, and on 30 June 2024, the total number of employees in the JGL Group was 1329, which is an increase of 88 employees when compared to the same period last year. These employees, every single one of them, are the Company's greatest asset. With JGL's propulsive growth across diverse cultures, it became essential to establish core values and behaviours

and embed them into the Company's current and future operations.

This led to the launch of the JGL Group Core Values project, which was introduced to all employees across all markets at the end of January 2024. The core values are the bedrock and guarantee of a company's sustainability, and at JGL they are as follows: Accountability, Respect, Unity and Sustainability. ACCOUNTABILITY, as we know that a company's well-being leads to employee well-being. RESPECT, as we want every member of the organization to feel respected and valued. UNITY, as we are building a global JGL community where we take care of each other. SUSTAINABILITY, as we create long-term value by caring for our social and natural environment.



The many differences and diverse aspects of our international expansion are a significant advantage. Integrating core values deeply into our company will further unite us and enhance our cohesion and resilience against new global market challenges.

A handwritten signature in blue ink, which appears to read 'Ivo Usmiani'.

Ivo Usmiani
President of the Board of Directors

Company Profile

NAME

JADRAN-GALENSKI LABORATORIJ d.d. / JGL d.d.

LOCATION OF HEADQUARTERS

Svilno 20, 51 000 Rijeka
Republic of Croatia

LOCATION OF OPERATIONS

The company's headquarters and production facilities are based in Rijeka, while the new logistics and distribution centre is located in Kukuljanovo. There are also two other offices in Croatia: in Zagreb and Split. In addition to Croatia, the company operates in various markets across Central and Eastern Europe. Beyond European Union, key markets include Russia, Ukraine, Kazakhstan, and Belarus.

JGL's products are present in 60 markets.


Other companies comprising the JGL Group are also owned by JGL. The pharmaceutical division of the business (JGL Pharma), the company's core business, encompasses the parent company JGL d.d. and its foreign subsidiaries, excluding Adrialab d.o.o., "Ljekarna Pablo" HI, Pablo d.o.o., "Goranske ljekarne" HI (merged with "Ljekarna Pablo" HI on July 26, 2024), and "Primorske ljekarne" HI.

JGL Pharmacy Museum is a subsidiary of JGL d.d. with headquarters at Užarska street 11, Rijeka.

Key manufacturing activities are located at three addresses:

- JGL d.d. – Svilno 20, 51 000 Rijeka, Republic of Croatia
- Adrialab d.o.o. – Pulac 4a, 51 000 Rijeka, Republic of Croatia
- JGL d.o.o Beograd-Sopot – Milosava Vlajića 110a, 11 450 Belgrade, Sopot, Serbia

An overview of affiliated companies in the JGL Group



List of JGL's subsidiaries with an indication of their core business

Subsidiary	Country	Core Business
Pablo d.o.o.	Croatia	Retail of pharmaceutical preparations and accessories
"Ljekarna Pablo" Health Institution	Croatia	Pharmaceutical activities
"Goranske ljekarne" Health Institution (merged with "Ljekarna Pablo" HI on July 26, 2024)	Croatia	Pharmaceutical activities
"Primorske ljekarne" Health Institution	Croatia	Pharmaceutical activities
Adrialab d.o.o.	Croatia	Production and sale of pharmaceutical preparations
JGL PPH d.o.o.	Croatia	Production and sale of pharmaceutical preparations
Jadran LLC Moscow	Russia	Sale of pharmaceutical preparations
Jadran Kazakhstan LLP	Kazakhstan	Sale of pharmaceutical preparations
JGL d.o.o. Beograd-Sopot	Serbia	Production and sale of pharmaceutical preparations
Farmis d.o.o. Sarajevo	Bosnia and Herzegovina	Sale of pharmaceutical preparations
Jadran - Galenski laboratorij d.o.o. Ljubljana	Slovenia	Sale of pharmaceutical preparations
JGL North America LLC * the company is not active	USA	Sale of pharmaceutical preparations

BUSINESS FOCUS

The JGL Group operates in eleven markets: Russia, Croatia, Ukraine, Kazakhstan, Belarus, Bosnia and Herzegovina, Serbia, Slovenia, North Macedonia, Kosovo, and Uzbekistan. Business is carried out through the parent company JGL d.d. which has representative offices in Ukraine, Belarus, Kazakhstan, Uzbekistan, Macedonia, Serbia, Bosnia and Hezegovina and Kosovo.


Affiliates are present in Croatia (Pablo d.o.o., “Ljekarna Pablo” HI, “Goranske ljekarne” HI (merged with "Ljekarna Pablo" HI on July 26, 2024), “Primorske ljekarne” HI, Adrialab d.o.o., JGL PPH d.o.o.), Russia (Jadran LLC), Kazakhstan (Jadran Kazakhstan LLP), Serbia (JGL d.o.o. Beograd-Sopot), Bosnia and Herzegovina (Farmis d.o.o. Sarajevo) and Slovenia (Jadran – Galenski laboratorij d.o.o.).

Since nearly 87 percent of JGL Pharma’s revenue is generated outside Croatia, JGL is an export-oriented company and all investments are directed accordingly.

Through distributors and B2B (Business-to-Business) relations with other companies, JGL products are present in 60 markets in total (Hungary, Switzerland, Italy, Greece, Romania, Poland...).

JGL cooperates with international partners through several cooperation models:

- through the distribution of JGL brands and cooperation through licensing, JGL products are widely present in Europe and the ASEAN and MENA regions,
- JGL cooperates with large pharmaceutical manufacturers through contract manufacturing.





Key Indicators

127.6




Total revenue
JGL Group
(in EUR million)

25.8



EBITDA JGL Group
(in EUR million)

1329



Number of employees
JGL Group

20.1



Profit before tax
JGL Group
(in EUR million)

198.8



Operating revenue
JGL Pharma
(in EUR million)

39.1



EBITDA MAT JGL Pharma
(in EUR million)

19.2



Profit before tax JGL Pharma
(in EUR million)

1.5



Net debt / EBITDA MAT JGL
Pharma

Overview of the results of
JGL Group, JGL Pharma,
and JGL d.d. on 30 June
2023 and 30 June 2024

in EUR million

	JGL GROUP		JGL PHARMA		JGL d.d.	
	30/06/2023	30/06/2024	30/06/2023	30/06/2024	30/06/2023	30/06/2024
Total revenue	103.7	127.6	88.4	108.8	67.3	79.5
Operating revenue	102.9	126.1	87.6	107.3	66.8	77.4
EBITDA	25.8	25.8	24.8	24.4	23.0	14.0
Profit before tax	15.2	20.1	14.7	19.2	13.4	10.4
EBITDA MAT ¹	44.9	41.7	43.1	39.1	37.6	22.5
Operating revenue MAT	211.8	234.1	179.2	198.8	132.8	142.7
EBITDA MAT MARGIN	21.2%	17.8%	24.0%	19.7%	28.3%	18.1%
Net debt	68.4	61.0	67.2	58.9	67.2	55.3
Net debt / EBITDA (MAT)	1.52	1.46	1.56	1.51	1.79	2.46
Net debt / capital	0.50	0.39	0.51	0.39	0.49	0.38
Debt ratio	0.48	0.46	0.47	0.45	0.40	0.44
Quick liquidity ratio	1.76	1.42	1.95	1.51	2.02	1.24

Significant financial data and indicators of JGL Group, Pharma and parent company JGL d.d. shown in the table indicate another successful period for JGL. We observe double-digit revenue growth, a healthy level of EBITDA MAT and high EBITDA MAT margin rates, as well as a reduction in net debt and an increase in group liquidity.

¹ Moving Annual Total

Sales Results

In the first half of 2024, JGL Pharma generated product sales revenue of EUR 101 million. Compared to the previous year, revenue increased by EUR 19.5 million or by 24%.


Total net sales revenue of JGL Pharma (in EUR million) on 30 June 2024



SALES BY PRODUCTION FORM


In the first half of 2023, the largest share of sales by production form belongs to sterile sprays, with a 35.8% share. They are followed by dry oral forms with a 21.7% share, main goods with 18.6%, aerosols with 11.1%, sterile drops with 4% and semi-solid forms, non-sterile solutions and other forms with a total of 8.8% share.

The share of production forms in the total net sales of JGL Pharma as of 30 June 2024



Sterile sprays recorded the biggest increase in sales compared to the previous year, with EUR 9 million higher sales, followed by dry oral forms with EUR 4.9 million higher sales.


Net sales revenue of JGL Pharma per production form (in EUR million)



SALES BY THERAPEUTIC AREA


Based on the structure of JGL Pharma's key therapeutic areas, the highest portion of net sales in the first half of 2024 comes from the flu and cold segment, accounting for 37.1%. Dermatology follows closely, representing 27.4% of sales, followed by the segment of other products at 15.8%, ophthalmology at 15.2%, and motion sickness at 4.5%.

The share of key therapeutic areas in the total sales of JGL Pharma as of 30 June 2024



The biggest increase in sales was recorded in the flu and cold segment, which grew by 21.2%, i.e. by EUR 6.5 million, in the first half of 2024. Compared to the previous year, the dermatology segment also recorded a sharp growth in the reporting period of EUR 8.1 million or 41.7%.

Net sales of JGL Pharma by key therapeutic areas (in EUR million)




SALES BY MARKET

JGL Pharma’s sales are monitored through two business segments: B2C (Business to Customer) and B2B (Business to Business). The B2C business model generates 84.6% of JGL Pharma's net sales across 20 markets, the largest of which are Russia, Croatia, Kazakhstan, Ukraine, Bosnia and Herzegovina, Belarus, and others.

Net sales reached a total of EUR 85.3 million, marking a 26% increase from EUR 67.9 million in the same period last year. During the reporting period, Kazakhstan saw the largest percentage increase in net sales, with an 86% rise, adding EUR 4.46 million in sales compared to the previous year. This growth increased its market share from 6% to 11%.



Overview of market share in total sales of JGL Pharma as of 30 June 2024



The B2B business model has a 15.3% share in total net sales of JGL Pharma, which is growing year by year. Total net sales reached EUR 15.4 million, marking a 15% increase from EUR 13.4 million in the same period last year.

Notably, Hungary experienced the largest increase in sales with EUR 0.7 million more compared to the previous reporting period, followed by Romania with a growth of EUR 0.5 million, and Saudi Arabia which experienced the same growth. Among the twenty markets where the Company operates through its B2B business model, Switzerland, Hungary, Romania, Czech Republic, Saudi Arabia, Italy, Greece, Singapore and Poland are the most significant.


SALES BY BRAND

The largest share in JGL Pharma is consistently held by the Aqua Maris brand, with a 24% share in net sales. In second place is Aknekutan with 21%, then Vizol S with 10%, Meralys with 8%, and Dramina with a 4% share, while the other brands make up 33% of JGL Pharma’s sales.



The Aqua Maris brand recorded a share increase to 24% in comparison to the previous year. However, the biggest increase in share was achieved by Aknekutan, going from 18% in 2023 to 21% in 2024, which represents a growth of 42%. Sales of Aknekutan in the first six months of 2024 are EUR 6.2 million higher compared to the same period in 2023.

Among the other key brands, it is worth mentioning Meralys, which in comparison to the previous period is growing at a rate of 30%, i.e., by EUR 1.8 million, and Vizol S, which has a growth of 61%.

Overview of B2B market share in total sales of JGL Pharma as of 30 June 2024



Brand share in total net sales of JGL Pharma in the first six months of 2024



1
No.1 NASAL
SPRAY

PRESERVATIVE
FREE

DECONGESTS
AND NOURISHES

jgl CROATIAN KNOWLEDGE
& EXPERTISE

meralys.com

IF YOU ASKED
YOUR NOSE,
IT WOULD
**CHOOSE
MERALYS.**



Read the leaflet carefully before using the product. For any questions or concerns, contact your doctor or a pharmacist.

After achieving the “double crown” with gold in the “Health” category and the “Grand Prix” at the Effie Awards Croatia, Meralys continued to shine in the first half of 2024 by winning the “Best of Europe: Health&Wellness” award at the Effie Awards Europe. The reporting period was also marked by the addi-

on of two major accolades: the “Worldwide Marketing Award” at the Nicholas Hall European Consumer Healthcare Conference, and the title of Croatia’s most effective brand for 2023, while JGL won the most effective advertiser title.

The Aqua Maris creative campaign beat strong competition and won the silver medal in the category Best on Market, Health and Pharmacy, among projects from across Croatia at the IdejaX national competition. The communication and creative concept of the “No Microplastics, No Worries” campaign was brought to life in cooperation with the Studio Tumpić/Prenc agency. In addition to the creative aspect recognised by the marketing community, the “No Microplastics, No Worries” campaign also has a more important, educa-

tional role, because it raises consumer awareness of an important environmental and public health challenge – microplastics, for which Aqua Maris remains the first and only brand to offer a solution.

Furthermore, the “X-Lab: A Future Without Microplastics” project won silver at the prestigious Native Advertising Institute Awards, standing out among international competitors.



Even the tiniest microplastic particles are harmful to our health, which is why Aqua Maris has never contained any.

Flush out bacteria and viruses safely and effectively.

No microplastics, no worries.



For everyone. Every day.




Employees

The total number of employees in the JGL Group on 30 June 2024 was 1329, which is an increase of 88 employees when compared to the same period last year.

Among these, most employees, 882 of them, work in Croatia (JGL d.d., Adrialab d.o.o., “Ljekarna Pablo” HI, “Primorske ljekarne” HI and Pablo d.o.o.), while 238 employees work in the Russian market.

As of 30 June 2024, 75% of the employees in the JGL Group are women, and 63% of the total employees have a university degree.



	30 June 2023	30 June 2024
JGL GROUP	1241	1329
Croatia	812	882
Russia	230	238
Ukraine	62	66
Kazakhstan	50	47
Serbia	28	28
Bosnia and Herzegovina	27	24
Belarus	20	22
Uzbekistan	0	10
Slovenia	6	6
North Macedonia	5	5
Kosovo	1	1

Overview of the number of employees of the JGL Group by market

	30 June 2023	30 June 2024	
Overview of the number of employees of the JGL Group by affiliated companies	JGL GROUP	1241	1329
	JGL d.d.	741	814
	Jadran LLC Moskva	227	235
	“Ljekarna Pablo” HI*	159	175
	Adrialab d.o.o.	32	34
	JGL d.o.o. Beograd-Sopot	28	28
	Farmis d.o.o. Sarajevo	27	24
	Ljekarne Muvrin HI	15	0
	“Primorske Ljekarne” HI	0	8
	Pablo d.o.o.	6	5
	JGL d.o.o. Ljubljana	6	6

**As of 27 May 2024 Employees from “Goranske Ljekarne” HI were transferred to “Ljekarna Pablo” HI (13)*



JGL Sales Platinum Club established with the aim of promoting excellence within the Company, increasing motivation, and talent retention

Areas and Activities



SCIENTIFIC OPERATIONS

During the reporting period, the first certification under the new EU regulation for medical products was completed for Vizol S Hydro Lipid Balance, an in-house product for patients and consumers with dry eye disease.

The upgrade and certification for the Vizol S 0.21%, Vizol S 0.4%, and Vizol S Intensive product lines were completed in line with the new EU medicinal product regulations and new EU MDR certificates were obtained. Certification for the Aqua Maris product line is ongoing. Upgrades for five medicinal products under EAEU regulations have been finalised in the reference country (RU).

The “Collaborative Research and Development of an Innovative Product for Treating Glaucoma and Associated Ocular Surface Disease – GlauCollab” project has been approved for cofinancing under the “Target Scientific Research” call with funds from the 2021-2026 National Recovery and Resilience Plan.

A project application for “New Formulation Platform for Poorly Soluble APIs with Potential Application for Dry Eye Disease - DEAP (Dry Eye API Platform)” was prepared and submitted in response to the public call for “Strengthening Strategic Partnerships for Innovation in the Process of Industrial Transition”. Evaluation of the application has started, and results and potential co-financing for the project are expected in 2025.

For the rest of 2024, intensive work and preparation of

files/documentation for registration procedures are in progress for:

- own technical documentation for Vizol S Digi Eye (eye drops, preservative free) aimed at consumers with significant exposure to digital screens; clinical amendments to the EU process are forthcoming at the end of 2024;
- own registration documentation for the preservative-free fixed combination drug for glaucoma treatment; with EU (2024) and EAEU (2025) procedures planned;
- own registration documentation/variation for eye drop antibiotics, technology transferred from Polpharma to JGL's pilot plant; with a planned EU variation (Type II).

The significant addition of technical documentation continues for existing products, including the MDR upgrade and the EAEU upgrade scheduled to begin at the end of 2025.



The first phase of the scientific study with athletes in cooperation with the Croatian Football Federation has been completed - Marijan Kustić and Mislav Vučić



MEDICAL AFFAIRS

The first phase of a scientific study with athletes, conducted in partnership with the Croatian Football Federation (HNS), was completed during reporting period and is now nearing the final stage of creating the report.

An expert analysis of the strategic areas of ophthalmology, dermatology, and the respiratory segment was conducted in order to develop a medical strategy for expanding indications in these areas, as well as an analysis of several potential new therapeutic areas, ensuring ongoing support for strategic activities.

A new standard for supporting promotional activities has been established, covering the creation and approval of promotional materials, presentations, and participation in professional events both domestically and internationally. Expert cooperation with health professionals from a number of therapeutic areas has intensified.

Standards for professional support in new product launches were set during this period, providing continuous assistance to key markets.

PHARMACEUTICAL AND TECHNOLOGICAL OPERATIONS


Between January and June 2024, we produced 28.1 million units of finished products, approximately equal to the previous year's figures for the same period.

Noteworthy activities in the first half of 2024 include the separation of dosing and finalisation lines and the implementation of security systems for marking vials with UV 2D codes.

The systematic coordinated efforts between the OpEx (Operational Excellence) team and finalisation operators, along with production and quality managers, achieved significant results during the reporting period. Daily monitoring of operations using the OpEx methodology, covering all functions, has been introduced at the Svilno 1 facility. OpEx activities relevant to finalisation have significantly improved visual handling of discarded products on packaging lines.

During the reporting period, systematic and intensive efforts in collaboration with Corporate HR led to the recruitment and integration of new employees to bolster JGL's Pharmaceutical and Technological Operations team.

Aligned with JGL Group's core values and commitment to socially responsible business practices and an inclusive society, a contract was signed during the reporting period with the DIP association from Rijeka for persons with disabilities to provide unpacking services to JGL.





QUALITY

During the first six months, significant and thorough inspections were conducted across all sterile and non-sterile production facilities, JGL laboratories, Svilno and Kukuljano-vo warehouses, and the quality assurance system.

HALMED carried out an inspection as part of the three-year cycle of supervision over the production of medicines, which led to the renewal of the EU GMP certificate. The inspection included a review of the new Pilot plant to obtain a GMP certificate, which will allow for the production of clinical and commercial batches. Another significant inspection was carried out by the Ministry of Health of the Republic of Belarus for the renewal of the GMP certificate applicable across the EAEU. For the first time, inspectors visited the new facilities and warehouses established under the INTEGRA project.

In addition to inspections, all audits were successfully completed in line with ISO standards (13485, 9001,

22000), along with audits of numerous cooperating partners. As in the previous periods, compliments were given to continuous improvements, infrastructure, and the expertise of employees.

In addition to ongoing operational, own project activities, and B2B project activities, implementing OpEx initiatives started in Quality Control to expedite processes and increase laboratory capacity. To efficiently handle mandatory training for both new and existing employees and to boost awareness of quality in the pharmaceutical industry, educational activities were introduced on the topic of quality assurance that use interactive digital content. These initiatives enhance the quality and streamline operations across all production segments, setting the stage for ongoing growth and development in the coming period.

KEY LAUNCHES


In the first half of 2024, eight products were successfully launched with a total value of EUR 140 thousand. Of the total number, six products were launched in JGL markets with own operations, while two products were launched in the B2B business model. By the end of the year, a further 31 new product launches are planned.

PRODUCT	MARKET
AKNET solution, 30 ml	Georgia (country)
JECOL cream, 25 g	Azerbaijan
VIZOL S INTENSIVE eye drops, 10 ml	Kyrgyzstan
VIZOL S 0.21% eye drops, 10 ml	Mongolia
VIZOL S 0.4% eye drops, 10 ml	Mongolia
JECOL cream, 25 g	Belarus
AQUA MARIS 4ALLERGY nasal spray	Indonesia
CLINDAMYCIN + BPO 10+50 mg/g, 30 g gel	Netherlands

KEY BRAND DEVELOPMENT

With the aim of maintaining competitive advantage of strategic brands in key markets, the so-called Brand Health Tracking system was deployed in the first half of 2024.

A uniform and standardised methodology developed in cooperation with our global partner Ipsos will track the impact of marketing initiatives on customers' brand perception and guide further strategic brand development while advancing brand management to a higher level.



The first Skin Health Symposium held at JGL with the aim of presenting innovative JGL products to dermatologists from the United Arab Emirates



B2B OPERATIONS

Eight contracts were finalised in the first half of 2024, yielding a five-year revenue of EUR 33 million; six for contracted production and two related to the JGL portfolio. During the same period, eight licensing contracts for prescription and over-the-counter products were signed for Southeast European markets, with a total five-year sales value of EUR 12.5 million.

Among other, a new partner was secured for Vizol S in the UK, a new product launched on the Italian market, and Antiakne gel is now available in the Netherlands. Additional product launches are anticipated in Australia, France, Estonia, Lithuania, Latvia, Denmark, and Poland by year-end.

A new product was added to the Aqua Maris line in Indonesia, while registration for the new Vizol S and Meralys HA products has begun in Saudi Arabia and the United Arab Emirates (UAE). Also of note were successful professional ophthalmology symposia in these markets and the first Skin Health Symposium for UAE dermatologists held in Rijeka.

During the reporting period Amikacin drops were launched. This was the first product for the strategic partner Polpharma. For the same partner launch of seven more products on the European markets are planned by year-end.

JGL also produced the first commercial batches of xylo-metazoline spray for a German strategic partner. The combined value of these activities is EUR 2.7 million.

To expand future B2B business and portfolio in existing markets, we are conducting a comprehensive analysis of the APAC region, including Australia, China, India, Japan, Korea, Malaysia, Philippines, Thailand, and Vietnam.

DIGITAL BUSINESS

JGL's e-commerce channel in Germany achieved a 35% average monthly sales growth rate during the first six months of 2024. This presence boosted the recognition of the Aqua Maris brand, particularly among mothers, where Aqua Maris Baby earned a "100% recommended" certificate from Buzzador's survey of 200 mothers. Vizol S eye drops have also been notably successful, quickly climbing to the top 10 best-selling brands on the reference online market due to high consumer interest since their launch.

It is worth mentioning that Aqua Maris is now available to customers in Austria, initiating the expansion of our e-commerce segment into the DACH region through Shop Apotheke, the largest e-commerce marketplace.



In the first half of 2024 transition to a new anti-virus solution was completed, offering additional tools and ensuring a higher level of IT security in line with our continued efforts in this area.

Also, the migration to new firewall systems was completed, enhancing connection security and establishing the groundwork for improved access segmentation within the JGL IT system using the "zero trust" model. These new systems also utilise AI tools for better and more accurate security threat detection.

INVESTMENTS IN NON-CURRENT ASSETS

During the first half of 2024, a total of EUR 6,245,838 was invested in the Group's non-current assets. Investments in intangible assets amount to EUR 2,173,319, of which EUR 313,429 relates to investments in computer programs, EUR 541,763 to the acquisition of licenses, registration of own products and trademark protection, and EUR 1,318,127 to investments in development projects.

Investments in tangible assets totalled EUR 4,072,519, including EUR 375,663 for buildings, EUR 1,134,305 for equipment procurement, and EUR 2,562,551 for furniture and transport assets.

During the first half of 2024, a total of EUR 3,547,585 was invested in JGL d.d.'s non-current assets. Investments in intangible assets amount to EUR 1,998,797, of which EUR 276,045 relates to investments in computer programs, EUR 404,625 to the acquisition of licenses, registration of own products, and trademark protection, and EUR 1,318,127 to investments in development projects.

Investments in tangible assets totalled EUR 1,548,788, including EUR 233,315 for buildings, EUR 906,004 for equipment procurement, and EUR 409,469 for furniture and transport assets.

Ivo Usmiani at the World
Entrepreneur Of The Year award



Above and Beyond Certificate in the
"Future" and "Innovation" categories
awarded to JGL

Mislav Vučić, Manager of the Year



AWARDS AND RECOGNITIONS

Ivo Usmiani, President of JGL's Board of Directors, was recognised as Entrepreneur of the Year 2023 during the reporting period, and represented Croatia at the EY World Entrepreneur of the Year finals in Monaco.

JGL's Chief Executive Officer, Mislav Vučić, won the CROMA 2023 Manager of the Year award in February of 2024 in the large enterprises category.

JGL is the winner of the Gold Award and Regional ESG Leader 2023 recognition in the category of Positive Impact on Society and the large companies subcategory. The company was also awarded the "Golden Key" in the 2023 Most Innovative Exporter category.

At the Finance and Investments Forum of the Lider weekly, JGL's investment project INTEGRA received two awards – "Lider Invest" for the best large investments in Croatia and "Employee Lider Invest" for an investment that contributed to employment the most.

During the reporting period JGL has been awarded the Above and Beyond Certificate in the "Future" and "Innovation" categories for the second year in a row. The company was also recognised with the Brand Leader award promoting top corporate brands in the region.

JGL PHARMACY MUSEUM

JGL and the JGL Pharmacy Museum put Rijeka on the map of the European Route of Historical Pharmacies and Medicinal Gardens, a unique project celebrating our common European roots and promoting intercultural dialogue, cultural identity, social cohesion, and sustainable human development. This route connects sites of historical significance, such as monastery pharmacies, historic pharmacies, historic libraries, botanical gardens, and medicinal gardens in regions across Europe. The JGL Pharmacy Museum is the first project partner from Croatia.

Eva Usmiani Capobianco
at "Hygeia Legacy" Forum
in March 2024



Structural Changes





BOARD OF DIRECTORS

The annual General Assembly of JGL d.d. held on 12 June 2024 re-elected five Management Board members with their term of office beginning on 31 December 2024. Given that the Board of Directors members' terms of office expire on 30 December 2024, the General Assembly decided to extend their terms for an additional five years.

Based on the Workers' Council decision of 26 April 2024, Renata Miculinić, was appointed to the JGL Board of Directors for a four-year term, starting on 19 June 2024.

ARTICLES OF INCORPORATION

By the decision of the Board of Directors of 11 April 2024, changes were made to the provisions of the Articles of Association in Art. 10 (share capital) and Art. 11 (number and code of shares). On 12 June 2024, the General Assembly amended the Articles of Association to include Art. 12.b, which addresses the approved share capital by which the company's share capital may be increased.

ESTABLISHMENTS

The parent company JGL d.d. established JADRAN Kazakhstan LLP (61/1 Markov str., block No. 2, office 122, Bostandyk district, Almaty 050040, Kazakhstan, BIN 240540032074) on 28 May 2024.

JADRAN Kazakhstan LLP is a new affiliated company and new member of JGL Group, 100% owned by JGL d.d. It operates as a limited liability partnership, similar to the Croatian form of a limited liability company. The company CEO is Irina Karakai from Ukraine. Alenka Jajac Knez is the president and member of the Supervisory Board, and other members are Mislav Vučić, Anton Barbir, and Dino Čoza Saršon.

The primary reason for establishing a new company is to support the parent company in sustaining continuous growth and increasing its market share in Kazakhstan. Planned share capital of the new company amounts to KZT 23,665,500 (EUR 50,000.00). The share capital of the company was paid on August 2, 2024.

The representative office of JGL d.d. was established in Uzbekistan on 12 February 2024. The representative office headquarters is in Tashkent (Yakkasarai district, Abdullah Kahkhara str., 56A), and Nodira Azimova from Uzbekistan has been appointed as the head of the representative office.

Share Transactions and New Share Issue



At the beginning of 2024, the Company had 40,966 own shares. By 30 June 2024, JGL allocated 4,895 own shares, so the number of own shares in the portfolio was 36,071 as at 30 June 2024. The share capital of the Company is divided into 1,276,129 shares, 1,240,058 of which are shares with voting rights, while those remaining are own shares.

NEW SHARE ISSUE


Under the authorisation from JGL's Articles of Association, the Board of Directors issued a Decision on the issue of 21,104 new LJ series shares, with a nominal value of EUR 13.00 per share. This increased the share capital from EUR 16,315,325.00 to EUR 16,589,677.00. The increase in the share capital was performed by entry into the court register of the Commercial Court in Rijeka, under No Tt-24/3328-3, on 25 April 2024.

Ownership structure of JGL
d.d. as of 30 June 2024

Source: JGL

Owner	Number of shares	% in capital	% in capital with voting rights
Ivo Usmiani	405,080	31.74%	32.67%
Sanja Katalinić	129,052	10.11%	10.41%
Gordana Saršon	124,470	9.75%	10.04%
Own shares	36,071	2.83%	
Eva Usmiani Capobianco	35,945	2.82%	2.90%
Grozdana Božić	31,544	2.47%	2.54%
Vesna Črnjarić	26,653	2.09%	2.15%
Đurđica Miletović - Forempoher	20,367	1.60%	1.64%
Marina Pulišić	19,509	1.53%	1.57%
Sanja Vujić Šmaguc	19,111	1.50%	1.54%
Small shareholders	428,327	33.56%	34.54%
TOTAL	1,276,129	100.00%	100.00%

Affiliated Companies



PHARMACEUTICAL BUSINESS

JADRAN LLC

Despite difficult and uncertain market conditions, the net sales of the Jadran LLC company in Moskow noted a growth of 52% when compared to the same period last year, while total earnings as of 30 June 2024 totalled EUR 46.1 million.

All key JGL brands, such as Aqua Maris, Rinomaris (Meralys), Aknekutan, and Optinol (Vizol S) have noted a growth greater than the growth of the market and key competitors in the reporting period, and have attained a significant position and respectable market shares. A report published by the independent agency DSM shows that the company has risen to 35th place in the ranking of pharmaceutical companies in Russia for the first five months of 2024, up eight spots from last year.

The Aqua Maris brand has maintained a leading position with regard to units sold and other financial indi-

cators in the segment of seawater-based nasal products, Aknekutan has maintained its leading position in the segment of acne-treating dermatological products, while the Optinol brand has a significant 17% market share in the segment of eye drops for dry eyes since May of 2024.


The reporting year is strategically important for the company due to the enhanced focus on other prescription and over-the-counter ophthalmic products launched in 2023, along with dermatological products and decongestants.

Despite significant investments in sales and marketing, the company achieved a pre-tax profit of EUR 9.2 million in addition to excellent market performance, marking a substantial improvement over the previous year. Building on successful sales results at the start of 2024, the company is focused on enhancing profits in the latter half of the year.

During reporting period Jadran LLC company won the “Employer of the Future” in the “Internal Career” category, a prestigious award that included the entire pharmaceutical industry in the country.

Natalya Golovkina, Dejan Jovanović, and Irina Bezhko receiving the award





JGL D.O.O. BEOGRAD-SOPOT

The first half of the 2024 business year was marked by further growth of revenue by 37% when compared to the same period last year. The company ended the semi-annual period with a profit before tax in the amount of EUR 286.7 thousand.

Total revenue amounted to EUR 2.6 million, of which EUR 1.3 million was generated from the sale of goods and products in the country, and the rest from the sale of own and transferred products abroad.

In the sales and marketing segment, the Company is continuing to focus, although on a smaller scale, on the segments of pharmacies, consumers, gynaecologists, and ophthalmologists. The digital campaign for Vizol S, Reflustat, and Prolife continued, as did the public health activity for patients entitled “Believe Your Eyes”.

In the field of production, the company is oriented to the production of drugs and dietary products for sale in Serbia and the surrounding markets. Early in 2024, the company initiated business development activities to maximise the production capacity of the Sopot facility, targeting new contract manufacturing partners and those willing to market JGL products under their own brands.

Revenue growth in the reporting period is based on the sale of goods and products on the Serbian market and the growth of product sales which were transferred to Sopot for all markets during 2020, primarily Lactogyn oral capsules and Feminal capsules.



FARMIS D.O.O. SARAJEVO

The first half of 2024 was extremely demanding in terms of goal realisation, but despite this performance was satisfactory. Farmis d.o.o. achieved total revenue of EUR 4 million, and a profit before tax of EUR 58.4 thousand.

JADRAN - GALENSKI LABORATORIJ D.O.O. LJUBLJANA

The first half of the 2024 business year for Jadran – Galenski laboratorij d.o.o. Ljubljana was marked by a growth of revenue of 13% when compared to the same period last year.

Key brands (Vizol S, Maresyl, Reflustat) recorded double-digit growth rates in the first six months, while the Aqua Maris brand maintained second position on the market with stable growth. Recognised brands (Carbo medicinalis, Dramina, Folacin) maintain leading market positions.

A total revenue of EUR 1.6 million was achieved and profit before tax totalled EUR 369.1 thousand.

JGL PPH D.O.O.

The company JGL PPH d.o.o. was established for the purposes of future operations pursuant to the Strategic Partnership Agreement concluded with pharmaceutical company Polfa Warszawa S.A. from Poland as a Special Purpose Vehicle (SPV) for implementation and monitoring of a specific business segment involving a foreign partner.

During the first half of 2024, total revenue of EUR 217.7 thousand and a loss of EUR 443.4 thousand were realised.

In the second half of 2024 it is expected an increase in revenue and profit due to new deliveries to the Polish partner.

“Ljekarna Pablo” will have a total of 34 pharmacy units by the end of the year



PHARMACY AND COSMETICS

“LJEKARNA PABLO” HI, “GORANSKE LJEKARNE” HI, “PRIMORSKE LJEKARNE” HI

In the first half of 2024, “Ljekarna Pablo” HI expanded to 32 pharmacy units, highlighted by the merger of two pharmacy units operating under “Goranske ljekarne” HI into “Ljekarna Pablo” HI.

ZU “Ljekarna Pablo” during the first half of 2024 realized total revenues in the amount of 16.3 million euros, and profit before taxes in the amount of 545.7 thousand euros.

Between the beginning of the year and the official merger with “Ljekarna Pablo” HI on 27 July 2024, “Goranske ljekarne” HI recorded total revenues of EUR 1.2 million and a profit before tax of EUR 63.7 thousand. In the period January-June 2024, the “Ljekarna Pablo” Health Institution achieved a total revenue of EUR 17.4 million, while profit before tax amounted to EUR 500 thousand. Total revenue of “Ljekarna Pablo” HI and “Goranske ljekarne” HI for the first six months of 2024 amounted to EUR 17.7 million.

In the first half of 2024, “Ljekarna Pablo” HI acquired founding rights for the “Primorske ljekarne” Health Institution, which began operating two pharmacy units on 11 March 2024. “Primorske ljekarne” HI realized total revenue in the amount of EUR 464.3 thousand and loss of EUR 10.3 thousand from the beginning of operation until the end of June 2024.

The business plan of “Ljekarna Pablo” HI includes merging two pharmacy units from “Primorske ljekarne” HI by year-end, resulting in 34 total pharmacy units and EUR 38 million in total revenue.

PABLO D.O.O.

“Pablo Health & Beauty” achieved total business revenue of EUR 303 thousand during the first six months of 2024, representing a growth of 36,4 percent compared to the same period last year.

While celebrating its second anniversary in June 2024, the company recorded a profit before tax of EUR 5.8 thousand for the January to June 2024 period. Collection of the necessary documentation for obtaining a pharmacy license at the address of this specialised store is still in progress.

New line for producing and dosing of non-sterile solutions has been established, followed by the production of the first batch of marshmallow syrup



ADRIALAB D.O.O.

In the first half of 2024, Adriabab completed the refurbishment of additional premises at the Pulac location, establishing a new line for producing and dosing of non-sterile solutions and starting the production of the first batch of marshmallow syrup. The project is valued at EUR 700 thousand and the production line has a capacity of two million units per year. Beyond meeting the needs of current production, there is potential for undertaking new, larger projects.

The optimisation of production processes led to a substantial increase in demand, resulting in a 37 percent revenue growth in the first half of the year compared to same period in 2023.


During the first half of 2024, the company achieved total revenues in the amount of 2.2 million euros, and profit before tax in the amount of 356.4 thousand euros.

The most significant growth was observed in B2B production (particularly with the parent company JGL d.d., which saw a 70 percent increase), however the wholesale channel also performed well (with a 68 percent increase), while the retail network maintained stable traffic (2 percent increase).

Our brand growth strategy is centred around five key products (Dječja mast JGL children's ointment, Vitalia D-Mannose, Holyplant syrups, Combusten, and Dermospray), and to further support this focus, the Marketing and Sales team will be reinforced with a new Market Director starting in the second quarter of 2024.

Operating profitability (EBITDA) is at 23 percent, which is a significant increase compared to 14 percent in the same period last year. It is mostly due to the growth of Adriabab, and to a lesser extent the alignment of intragroup transactions in the second half of 2023.

Financial Performance



Total revenue of the pharmaceutical business (JGL Pharma) in the first half of 2024 amounts to EUR 108.8 million, and profit before tax to EUR 19.2 million, which makes for a record breaking semi-annual performance for JGL Pharma.

When compared to the same period last year, this translates to an increase in total revenue of 23%. The Moving Annual Total of JGL Pharma reached EUR 198.8 million in the last 12 months. The EBITDA MAT stands at EUR 39.1 million, with a EBITDA MAT margin of 19.7%.

Total revenue of the parent company JGL d.d. grew by 18% compared to the same period last year and reached EUR 79.5 million, while the profit before tax amounted to EUR 10.4 million. The operating revenue MAT of JGL d.d. in the first half of 2024 recorded an increase of 8% compared to the same period last year and amounted to EUR 142.7 million with EBITDA MAT of EUR 22.5 million and an EBITDA MAT margin of 18.1%. Sales revenue growth rates are high, however profit before tax is slightly lower compared to the previous period. Performance for the first half of 2024 was primarily influenced by changes in inventory value and increased expenses due to rising fixed operating costs. Due to the Russian ruble's appreciation against the euro in the first half of 2024, our financial revenue exceeded our financial expenses, leading to a positive net effect of just over 1 million euro.

Total revenues of the JGL Group increased by 22.5% compared to the same period last year and amount to 127.6 million euros, while profit before tax amounts to 20.1 million euros, which is an increase of almost 32% compared to the same period last year. MAT Operating income of Group JGL in the first half of 2024 recorded an increase of 10% compared to the same period last year and amounted to EUR 234.1 million with EBITDA MAT of EUR 41.7 million and an EBITDA MAT margin of 17.8%.

The investment cycle was completed in 2023, and the net debt was reduced in the first half of 2024 by paying off existing loans. Additionally, due to good results, the net debt/EBITDA of the group, or rather the parent company, JGL d.d., is significantly smaller than it was in the same period last year.

JGL's assets grew by 5% during 2024. Significant changes can be seen when it comes to current assets due to reduced trade receivables because of the increased collection of accounts receivable, and an increase in inventory and money at hand. Current liabilities for loans and leasing were reduced by regular repayments of HBOR loans and leasing, while liabilities to suppliers increased due to the greater need for raw materials and other production materials.

Despite the complex political situation on the sales markets, as well as the effect of the new investment, the JGL Group has very satisfactory financial indicators. At the end of the first half of the year, the JGL Group indebtedness factor (net debt/EBITDA MAT) totalled 1.46 while the debt ratio was 0.46 and the quick liquidity ratio was 1.42.

Balance sheet of the JGL
Group and JGL Pharma
JGL Pharma (in EUR mil.)
² as at 31 December 2023
and 30 June 2024

	JGL GROUP			JGL PHARMA		
	30 June 2023	30 June 2024	Index	30 June 2023	30 June 2024	Index
Operating revenue	102.9	126.1	123	87.6	107.3	122
Sales revenue	102.4	125.2	122	87.1	106.3	122
Other revenue	0.5	0.9	167	0.5	1.0	195
Operating expenses	83.1	105.9	127	68.4	88.1	129
Change in inventory value	-5.8	0.8	-	-5.8	0.8	-
Material costs	60.6	68.9	114	48.8	54.7	112
Personnel costs	15.3	18.4	120	13.2	15.8	120
Other costs	13.0	17.8	138	12.2	16.8	139
Finance revenue	0.8	1.5	196	0.8	1.5	196
Finance expenses	5.4	1.6	30	5.3	1.5	29
Total revenue	103.7	127.6	123	88.4	108.8	123
Total expenses	88.5	107.5	122	73.7	89.6	122
Profit before tax	15.2	20.1	132	14.7	19.2	131

² The balance sheet is shown according to the management classification and is not identical in layout to the balance sheet prescribed by IFRS standards

Balance sheet of the JGL
Group and JGL Pharma
JGL Pharma (in EUR
mil.)² as at 31 December
2023 and 30 June 2024

	JGL D.D.		
	30 June 2023	30 June 2024	Index
Operating revenue	66.8	77.4	116
Sales revenue	66.5	77.1	116
Other revenue	0.3	0.3	85
Operating expenses	49.0	68.1	139
Change in inventory value	-5.8	0.8	-
Material costs	35.7	41.3	115
Personnel costs	8.9	11.4	128
Other costs	6.2	9.8	158
Finance revenue	0.5	2.1	375
Finance expenses	4.9	1.0	21
Total revenue	67.3	79.5	118
Total expenses	53.9	69.1	128
Profit before tax	13.4	10.4	77

² The balance sheet is shown according to the management classification and is not identical in layout to the balance sheet prescribed by IFRS standards

Balance sheet of the JGL Group (in EUR mil.)³ as at 31 December 2023 and 30 June 2024

	JGL GROUP			JGL PHARMA		
	31 December 2023	30 June 2024	Index	31 December 2023	30 June 2024	Index
Assets	273.7	302.6	111	258.4	286.3	111
Non-current assets	146.6	148.2	101	140.8	142	101
Current assets	126.1	153.7	122	116.8	143.6	123
Inventory	46.4	54.7	118	42.1	49.4	118
Receivables	55.8	65.4	117	51.8	61.7	119
Current financial assets	3.0	2.9	99	3.0	2.9	99
Cash at bank and in hand	20.9	30.6	147	19.9	29.6	148
Prepaid expenses and accrued revenue	1.0	0.8	80	0.8	0.7	82
Liabilities	273.7	302.6	111	258.4	286.3	111
Capital and reserves	139.4	157.5	113	134.4	151.5	113
Non-current provisions	0.6	0.6	98	0.5	0.5	100
Non-current liabilities	65.8	68.2	104	63.4	65.5	103
Liabilities for leasing and banks	65.0	66.7	103	63.2	64.8	103
Deferred tax liability	0.8	1.5	177	0.2	0.7	436
Current liabilities	63.6	69.8	110	56.1	62.5	111
Suppliers	29.6	38.1	129	24.6	33.1	135
Financial liabilities	25.9	27.9	108	24.2	26.5	109
Other current liabilities	8.1	3.8	48	7.3	2.9	39
Accrued expenses, deferred revenue	4.3	6.5	153	4.0	6.3	153

³ The balance sheet is shown according to the management classification and is not identical in layout to the balance sheet prescribed by IFRS standards

Balance sheet of the JGL Group (in EUR mil.)³ as at 31 December 2023 and 30 June 2024

JGL D.D.

	31 December 2023	30 June 2024	Index
Assets	250.3	262.9	105
Non-current assets	149.3	148.4	99
Current assets	100.2	113.9	114
Inventory	40.7	47.7	117
Receivables	40.1	37.9	95
Current financial assets	2.9	2.9	99
Cash at bank and in hand	16.5	25.4	154
Prepaid expenses and accrued revenue	0.8	0.6	76
Liabilities	250.3	262.9	105
Capital and reserves	136.9	145.0	106
Non-current provisions	0.5	0.5	100
Non-current liabilities	61.9	62.2	100
Liabilities for leasing and banks	61.9	62.2	100
Deferred tax liability	0	0.0	-
Current liabilities	48.9	53.3	109
Suppliers	18.1	29.1	161
Financial liabilities	23.6	21.4	91
Other current liabilities	7.2	2.8	38
Accrued expenses, deferred revenue	2.1	1.9	93

³ The balance sheet is shown according to the management classification and is not identical in layout to the balance sheet prescribed by IFRS standards

ACCOUNTING POLICIES

When creating the financial statement for the semi-annual reporting period, as in the previous annual reports, no changes were made when applying accounting policies.

OFF-BALANCE SHEET RECORDS

Financial liabilities of the Group which were not included in the balance sheet and are monitored through off-balance sheet records are liabilities towards received and given guarantees and approved bank lines.

The most significant change is in the credit lines of the Company's banks and the Company issued guarantees.

Off-balance sheet records
of JGL Group and JGL
d.d. as at 31 December
2023 and 30 June 2024

	GROUP		COMPANY	
	31 December 2023	30 June 2024	31 December 2023	30 June 2024
Credit lines with banks	14,876,501	16,945,560	10,660,000	12,660,000
Issued guarantees	5,175,774	7,940,379	5,079,291	7,875,698
Received guarantees	9,987,589	11,994,352	2,417,184	1,727,833
Other	447,153	435,761	447,153	435,761
Total	30,487,018	37,316,052	18,603,628	22,699,292





Business Risks



Business risk management is one of the key tasks handled by the JGL Group management team in 2024. Technological advances, climate change, and shifting geopolitical landscapes speed up change and increase the complexity of business risks. In the VUCA (Volatility, Uncertainty, Complexity, Ambiguity) era, managing known risks is not enough; the key is recognizing and quickly adapting to new, unknown risks.

The JGL Group's agile operations enable it to quickly adapt to sudden changes, recognise risks in a timely manner, and minimise their negative impacts.

The Company remains focused on making progress and the continuous enhancement of business processes to achieve long-term value and stability for its partners, shareholders, employees, and society as a whole. One of the tools for effective corporate governance to achieve long-term value is Enterprise Risk Management. JGL Group continuously works on identifying, understanding, and promptly evaluating business risks to transform them into new opportunities for growth and development and ensure stable and sustainable business operations in the long term.

BUSINESS ENVIRONMENT RISK

Business environment risk includes geopolitical, macroeconomic, and social risks in all markets in which the JGL Group operates. The JGL Group cannot directly influence this type of risk. Conversely, they directly influence the operation of the Group.

Alongside geopolitical risk, cyber risk and the lack of skilled labour rank high on the risk scale in 2024. Although macroeconomic risks and energy crisis-related risks remain, they have decreased in significance.

Social and geopolitical risk stems from ongoing regional conflicts worldwide, which have the potential to escalate and directly impact disruptions in the supply chain and commodity prices. All of this contributes to Business Interruption Risk (BI), a new term that

captures the interconnectedness of these risks in an increasingly volatile global business environment and the heavy reliance on supply chains for key products and services. In recent years, the global supply chain has faced challenges due to political turmoil and the ever-growing demands of e-commerce.

Despite previous disruptions, the global supply chain is normalising in 2024. The JGL Group mitigates supply chain risks by developing alternative suppliers, enhancing business operations, managing continuity, and identifying and addressing supply chain bottlenecks. However, disruptions in the global supply chain remain one of the main business risks in a rapidly changing world. Global supply chains are being challenged to become more resilient, and many view automation and the adoption of artificial intelligence (AI) as crucial tools for strengthening the supply chain.

Another significant risk of the business environment is the macroeconomic uncertainty caused by major changes in inflation and interest rates. Normalisation of these rates is expected in 2024. However, uncertainty remains present due to geopolitical risk as a result of the conflict and parliamentary elections in the current year.

FINANCIAL RISKS


In its ordinary course of business, the JGL Group is exposed to various financial risks which are connected to foreign currency, interest rate, credit, market, and liquidity risks. The Group is monitoring these risks and trying to reduce their potential effect on the companies' financial exposure.

FOREIGN CURRENCY RISK

The Group is exposed to risks of foreign exchange rate fluctuations during procurement and sales denominated in foreign currencies. Furthermore, the Group is exposed to transaction risk, which is the risk of a negative impact of the exchange rate on cash flows from operating activities, as well as balance sheet risk, which manifests as a lower value of net monetary assets in foreign currencies. Currency risk is also a factor in presenting the performance of foreign subsidiaries sin-

Exposure to the currency risk of changes in the RUB exchange rate in 2024

Source: (<https://finance.yahoo.com>)



ce their results are reported in euros in the consolidated financial statements.

The introduction of the euro as the official currency in Croatia significantly reduced the currency risk for the Group in 2024. The risk of the changing exchange rate of the euro against the ruble remains the most significant currency risk.

The exposure to foreign currency risk is constantly monitored, and hedge accounting is used as necessary. The decision on hedging depends on the currency in which the receivables are denominated, the type of hedge accounting, and its price. As of 30 June 2024, the parent company had no active forward contracts.

Exposure to currency risk of changes in the EUR/RUB exchange rate

JGL d.d. invoices products for the Russian market in the Russian ruble. During 2024, the political and economic crisis, the war between Russia and Ukraine, and the subsequent sanctions implemented by the EU and the US influenced the value of the ruble, along with other factors such as the price of oil on the global markets and the monetary policy implemented by the Russian

Central Bank (RCB), including interest rate increases, restrictions on foreign currency sales, inflation control measures, etc.

During 2024, there was a gradual appreciation of the Russian ruble relative to the euro, indicating a return to realistic levels of the ruble's value (90-100 RUB to the euro). Volatile exchange rate fluctuations generate significant exchange rate differences for the JGL Group. The ruble exchange rate fluctuated between 91 and 102 in the first half of 2024. Throughout 2024, the ruble exchange rate risk was managed by narrowing the gap between foreign currency assets and liabilities and implementing a policy for handling ruble funds in accounts.

ACCOUNTS RECEIVABLE RISK

Credit risk refers to the risk of customers failing to make payments or defaulting on their obligations within the agreed timeframes, thereby posing a risk to the collection of receivables.

The JGL Group's accounts receivable risk is significantly diversified through the distribution of receivables across various geographical areas and customers. The Group safeguards against this risk by obtaining payment insurance instruments, selecting customers

based on the evaluation of their creditworthiness, and insuring export receivables.

Export accounts receivables are insured by the Croatian Bank for Reconstruction and Development (HBOR) and the Croatian Credit Insurance (HKO). The total insured amount of foreign receivables in 2024 was EUR 25 million. Most foreign trade receivables that have an arranged deferral of payment are insured. Information on customers is collected together with insurers, and the risk, creditworthiness, and liquidity of insured customers are systematically monitored, with approved limits reviewed annually. In the last few years, the Group has recorded a constant increase of the insured amounts as a result of growing turnover from existing customers and insuring new customers. Receivables are analysed weekly, and all measures needed to collect them are taken.

The receivables of the associated company Jadran LLC are insured in Russia through the insurance company Euler Hermes and SBERBANK. The total insured credit limit for customers in Russia in 2024 was EUR 44 million.

Due to the current situation in Ukraine, Russia, and Belarus, special attention is focused on managing receivables in these markets through increased monitoring and constant communication with insurers. Since the beginning of the crisis, deliveries to these markets have been conducted according to an extraordinary model and have a special status with insurers.

CAPITAL MANAGEMENT

The JGL Group manages its capital by regulating the proportion of self-financing versus financing from external sources. Financing from other sources is based on non-current assets with favourable interest rates and does not represent a burden on the Company's liquidity. With regard to debt type, the parent company has long-term liabilities for received loans, leasing, and issued bonds. Long-term loan liabilities consist of three long-term loans obtained from the Croatian Bank for Reconstruction and Development (HBOR). The liability for the long-term HBOR loan used to finance the investment in the Svilno 2 production plant

amounts to EUR 13.2. The initial amount of this loan was EUR 31.8 million, with a repayment term of nine years. The loan will be fully repaid in 2027.

In 2020, the parent company made a new investment, INTEGRA, which included expanding production capacity, equipping a development laboratory, creating a new pilot plant, developing office space, and building a logistics centre. The investment is partially self-financed and partially financed by a long-term loan from the Croatian Bank for Reconstruction and Development in the amount of EUR 39.3 million with a favourable fixed interest rate. The loan was fully utilised in 2023, with a repayment term of nine years, with repayment of the principal commencing in 2026 and the final maturity scheduled for 2035.

The third long-term loan secured from HBOR for financing working capital totals EUR 13.3 million. This loan has a fixed interest rate, a one-year grace period, and a five-year repayment term.

As at 30 June 2024, the parent company has liabilities under the issue of bonds under the code HRJD-GLO24XA2 in the amount of EUR 17.0 million, with a maturity date of 18 December 2024; the interest on these bonds is fixed. Long-term lease liabilities are divided into those for operating and financial leases, accompanied by four- or five-year contracts with low fixed interest rates.

This year, JGL d.d. is considering the possibility of issuing new debt securities (bonds) on the domestic capital market. Proceeds from the potential bond issue would be utilised to refinance the repayment of the mentioned bonds upon maturity and to address other corporate needs.

In addition to long-term debt, JGL Group also has short-term loans that mature in the second half of 2024. Ljekarna Pablo HI has short-term loan obligation for working capital in the amount of EUR 1.1 million. Jadran LLC has short-term loan obligation for working capital in the amount of RUB 398 million (EUR 4 million).



Interest rate risk

The Group's interest rate risk arises from long-term loans, leases, and bonds issued on the liabilities side, and contracted short-term deposits on the assets side.

Within the JGL Group, the parent company is indebted and, therefore, bears most of the interest rate risk. If we consider that the majority of the long-term interest debt is contracted with a fixed interest rate that is more favourable than the current market interest rate, the parent company is minimally exposed to the interest rate risk.

In addition to long-term loans, Group's Croatian member Ljekarna Pablo HI and Russian member Jadran LLC also have short-term loans with variable interest rates. The exposure to interest rate risk is constantly monitored, and hedge accounting is used as necessary. The decision on hedging depends on the current market interest rates, the type of hedge accounting, and its price. In the first half of 2024, the JGL Group did not use derivative instruments for active protection against interest rate risk exposure (cash flow interest rate risk and fair value interest rate risk).

Throughout 2024, surplus funds from the JGL Group were allocated partly to time deposits with banks, thereby partially preventing the interest rate risk (interest rates on deposits in 2024 were higher than the agreed interest rates on long-term loans in Croatia).

For short-term financing, JGL uses funds from the lines of short-term credit arranged with its commercial banks at favourable interest rates which are reviewed annually.

In the first half of 2024, there was a continued trend of decreasing inflation rates observed both in the Eurozone and the US. This trend prompted central banks to decelerate the pace of interest rate hikes, signalling a potential end to the rate hike cycle.


Liquidity risk

Liquidity risk is the risk of the inability to convert certain forms of assets into cash (asset liquidity risk) or the risk of the inability to balance short-term payment capabilities on the one hand and short-term liabilities on the other (cash flow risk). Consequently, the JGL Group consistently focuses on liquidity management and holding sufficient cash reserves.

The Group manages this risk by monitoring and planning cash flow (Cash Flow Forecast) on a monthly basis and by maintaining sufficient levels of liquid assets and working capital. Liquidity risk is further mitigated by contracting favourable short-term credit lines with various commercial banks that allow for the rapid withdrawal of funds.

In the first half of 2024, the JGL Group had short-term credit lines in euros with commercial banks approved and contracted in the total amount of EUR 17 million. The above credit lines acted as a liquidity reserve, with the affiliated company Ljekarna Pablo HI utilising EUR 1.1 million during 2024, while JADRAN LLC utilised RUB 398 million (EUR 4 million) in Russia. Out of the total contracted amount of EUR 13 million within the JGL Group, EUR 4 million is available to the affiliated company LLC Jadran in Russia, while the Croatian affiliate Ljekarna Pablo HI, as a co-debtor under the parent company, has access to EUR 4 million.

To mitigate liquidity risk effectively, it is crucial to proactively monitor and identify potential sources of liquidity risk. Factors like inflationary pressures, supply chain disruptions, or geopolitical tensions are potential sources of liquidity risk. They can impact cash flows and access to finance, posing risks to liquidity. Therefore, businesses must remain agile and react swiftly to these challenges to mitigate liquidity risk effectively. The JGL Group mitigates this risk by closely monitoring financial liquidity indicators (general liquidity, accelerated liquidity, and net working capital), maintaining adequate liquidity levels and implementing cash flow forecasting and monitoring practices.



Future Development



Given global geopolitical tensions and economic uncertainties, predicting what the coming year holds is challenging. Managing a company in VUCA (Volatility, Uncertainty, Complexity, Ambiguity) times requires agility, flexibility and adaptability. Our JGL strategy is based on three global megatrends and enables us to respond in a flexible and innovative way to crises, sudden changes in the market, and increasing customer expectations.

Through detailed strategic planning and continued adjustments, we demonstrated our ability to sustain a stable and profitable business even amidst challenging circumstances. Despite the obstacles, we ensured a steady supply to our customers, proving that even amid market shocks and domestic economic challenges we could achieve growth and innovation.

At JGL, we are always thinking about new business opportunities, including new investments. The past period was characterised by growth in productivity, innovation, and the expansion of our presence worldwide. We were investing in intellectual properties for our innovative and complex products, and advancing operations based on the latest scientific and technological breakthroughs with regard to products. To achieve this, we must enhance and deepen our expertise and cultivate a mindset to adapt to turbulent daily external changes, learn from them and leverage them effectively. Strategic areas of JGL's ESG strategy include climate

change, water and marine resources, own workforce, and business-related behaviour. For 2024, we have defined initiatives that provide a clear direction and set qualitative goals for each of our priority topics. By integrating ESG principles into our operations, we not only mitigate negative environmental effects but also foster positive social change and sustainable management practices, ensuring the satisfaction of all our stakeholders.

JGL has always been and remains focused on export, global market, innovations, and new products... which means our ongoing success is closely tied to our ability to make an impact in the global health market. Our focus in the domestic market is on maintaining stable business conditions, ensuring access to reasonably priced capital with minimum fiscal constraints. If we can participate in programs that drive new and green technologies, even better.

JGL is a successful, agile, smart company whose products are recognised and trusted by patients and consumers. With targeted investments in new markets and technologies, and existing and new employees, I firmly believe that we will keep advancing along our ambitious and sustainable path.



Mislav Vučić
Chief Executive Officer

Financial Reports JGL Group

63	Balance sheet
67	Income statement
71	Statement of cash flows – direct method
73	Statement of changes in equity
75	Notes accompanying financial statements – pfi

BALANCE SHEET
Status as at 30/06/2024
In euros

Company:
JGL GROUP

Position name 1	AOP marking 2	Last day of previous business year 3	As at reporting date of current period 4
ASSETS			
A RECEIVABLES FOR REGISTERED BUT UNPAID CAPITAL	001	0	0
B NON-CURRENT ASSETS (AOP 003+010+020+031+036)	002	146,590,175	148,161,764
I. INTANGIBLE ASSETS (AOP 004 to 009)	003	23,913,692	25,550,823
1 Development costs	004	3,077,481	2,920,432
2 Concessions, patents, licences, brand and service name, software and other rights	005	7,841,702	8,233,258
3 Goodwill	006	2,870,985	2,870,985
4 Advance payments for the procurement of intangible assets	007	0	0
5 Intangible assets in preparation	008	7,978,316	9,451,431
6 Other intangible assets	009	2,145,208	2,074,717
II. TANGIBLE ASSETS (AOP 011 to 019)	010	118,633,719	118,014,088
1 Land	011	6,002,197	6,002,220
2 Buildings	012	52,850,545	51,925,770
3 Plants and equipment	013	50,817,832	49,165,762
4 Tools, plant inventory and transportation assets	014	4,927,644	6,717,590
5 Biological assets	015	0	0
6 Advance payments for tangible assets	016	0	0
7 Tangible assets in preparation	017	1,532,486	1,698,134
8 Other tangible assets	018	165,272	166,870
9 Investment property	019	2,337,743	2,337,742
III. NON-CURRENT FINANCIAL ASSETS (AOP 021 to 030)	020	271,699	273,479
1 Investment in shares (stocks) of enterprises within the group	021	0	0
2 Investment in other securities of enterprises within the group	022	0	0
3 Loans granted, deposits and similar to enterprises within the group	023	0	0
4 Investment in shares (stocks) of companies connected with participating interests	024	87,905	89,022
5 Investment in other securities of companies connected with participating interests	025	0	0
6 Loans granted, deposits and similar to companies connected with participating interests	026	0	0
7 Investments in securities	027	156,955	157,618
8 Given loans, deposits and similar	028	26,839	26,839
9 Other investments calculated using the equity method	029	0	0
10 Other long-term financial assets	030	0	0
IV. RECEIVABLES (AOP 032 to 035)	031	10	10
1 Receivables of enterprises within the group	032	0	0

BALANCE SHEET
Status as at 30/06/2024
In euros

Company:
JGL GROUP

Position name 1	AOP marking 2	Last day of previous business year 3	As at reporting date of current period 4
2 Receivables of companies connected with participating interests	033	0	0
3 Trade receivables	034	0	0
4 Other receivables	035	10	10
V. DEFERRED TAX ASSETS	036	3,771,055	4,323,364
C CURRENT ASSETS (AOP 038+046+053+063)	037	126,055,279	153,652,606
I. INVENTORIES (AOP 039 to 045)	038	46,447,995	54,644,395
1 Raw materials	039	19,493,020	26,135,545
2 Work in progress	040	5,469	325,575
3 Finished goods	041	16,947,068	15,102,947
4 Trade goods	042	10,002,438	13,078,546
5 Advance payments for inventory	043	0	1,782
6 Long-term assets intended for sale	044	0	0
7 Biological assets	045	0	0
II. RECEIVABLES (AOP 047 to 052)	046	55,750,469	65,441,485
1 Receivables of enterprises within the group	047	0	0
2 Receivables of companies connected with participating interests	048	0	0
3 Trade receivables	049	49,072,136	58,547,796
4 Receivables from employees and company members	050	21,037	109,488
5 Receivables from the Government and other institutions	051	5,337,465	5,671,029
6 Other receivables	052	1,319,831	1,113,172
III. CURRENT FINANCIAL ASSETS (AOP 054 to 062)	053	2,966,015	2,928,089
1 Investment in shares (stocks) of enterprises within the group	054	0	0
2 Investment in other securities of enterprises within the group	055	0	0
3 Loans granted, deposits and similar to enterprises within the group	056	0	0
4 Investment in shares (stocks) of companies connected with participating interests	057	0	0
5 Investment in other securities of companies connected with participating interests	058	0	0
6 Loans granted, deposits and similar to companies connected with participating interests	059	0	0
7 Investments in securities	060	0	0
8 Given loans, deposits and similar	061	46,210	37,732
9 Other financial assets	062	2,919,805	2,890,357
IV. CASH AT BANK AND IN HAND	063	20,890,800	30,638,637
D PREPAID EXPENSES AND ACCRUED REVENUE	064	1,036,562	827,636
E TOTAL ASSETS (AOP 001+002+037+064)	065	273,682,016	302,642,006
F OFF-BALANCE ENTRIES	066	18,603,628	22,715,746

BALANCE SHEET
Status as at 30/06/2024
In euros

Company:
JGL GROUP

Position name	AOP marking	Last day of previous business year	As at reporting date of current period
1	2	3	4
LIABILITIES			
A CAPITAL AND RESERVES	067	139,435,208	157,467,417
(AOP 068 to 070+076+077+083+086+089)			
I. SHARE (SUBSCRIBED) CAPITAL	068	16,315,325	16,589,677
II. CAPITAL RESERVES	069	6,618,482	8,518,475
III. PROFIT RESERVES (AOP 071+072-073+074+075)	070	12,022,085	12,022,085
1 Legal reserves	071	11,587,855	11,587,855
2 Reserves for own shares	072	688,771	625,136
3 Own shares and interests (deductible item)	073	-532,558	-468,923
4 Statutory reserves	074	0	0
5 Other reserves	075	278,017	278,017
IV. REVALUATION RESERVES	076	0	0
V. FAIR VALUE RESERVES AND OTHER (AOP 078 to 082)	077	-278,088	-149,352
1 Fair value of financial assets through other comprehensive income (in other words, available for sale)	078	0	0
2 Efficient part of cash flow protection	079	0	0
3 Efficient part of net abroad investment protection	080	0	0
4 Other fair value reserves	081	0	0
5 Foreign exchange gains/losses from conversion of operations abroad (consolidation)	082	-278,088	-149,352
VI. PROFIT OR LOSS BROUGHT FORWARD (AOP 084-085)	083	85,174,931	100,385,391
1 Profit brought forward	084	85,174,931	100,385,391
2 Loss brought forward	085	0	0
VII. BUSINESS YEAR PROFIT OR LOSS (AOP 087-088)	086	19,582,473	20,101,141
1 Profit for the financial year	087	19,582,473	20,101,141
2 Loss for the financial year	088	0	0
VIII. MINORITY (NON-CONTROLLING) INTEREST	089	0	0
B PROVISIONS (AOP 091 to 096)	090	582,825	568,467
1 Provisions for pensions, severances and similar obligations	091	484,617	470,259
2 Provisions for taxation	092	0	0
3 Provisions for initiated court disputes	093	98,208	98,208
4 Provisions for costs of regenerating natural resources	094	0	0
5 Provisions for costs in warranty period	095	0	0
6 Other provisions	096	0	0

BALANCE SHEET
Status as at 30/06/2024
In euros

Company:
JGL GROUP

Position name	AOP marking	Last day of previous business year	As at reporting date of current period
1	2	3	4
C LONG-TERM LIABILITIES (AOP 098 to 108)	097	65,813,777	68,201,723
1 Liabilities towards enterprises within the group	098	0	0
2 Liabilities for loans, deposits and similar for enterprises within the group	099	0	0
3 Liabilities towards companies connected with participating interests	100	0	0
4 Liabilities for loans, deposits and similar to companies connected with participating interests	101	0	0
5 Liabilities for loans, deposits and similar	102	0	0
6 Liabilities towards banks and other financial institutions	103	64,975,001	66,720,032
7 Liabilities for advance payments	104	0	0
8 Trade payables	105	225	225
9 Liabilities arising from securities	106	0	0
10 Other long-term liabilities	107	0	0
11 Deferred tax liability	108	838,551	1,481,466
D SHORT-TERM LIABILITIES (AOP 110 to 123)	109	63,552,362	69,839,199
1 Liabilities towards enterprises within the group	110	0	0
2 Liabilities for loans, deposits and similar for enterprises within the group	111	0	0
3 Liabilities towards companies connected with participating interests	112	0	0
4 Liabilities for loans, deposits and similar to companies connected with participating interests	113	0	0
5 Liabilities for loans, deposits and similar	114	0	0
6 Liabilities towards banks and other financial institutions	115	8,938,272	10,892,033
7 Liabilities for advance payments	116	117,020	8,961
8 Trade payables	117	29,618,502	38,141,623
9 Liabilities arising from securities	118	16,941,677	16,965,098
10 Liabilities towards employees	119	3,887,128	1,940,665
11 Liabilities for taxes, contributions and similar payments	120	3,268,894	1,308,125
12 Liabilities due to share in result	121	62,112	140,468
13 Liabilities due to long-term assets intended for sale	122	0	0
14 Other current liabilities	123	718,757	442,226
E ACCRUED EXPENSES AND DEFERRED REVENUE	124	4,297,844	6,565,200
F TOTAL – LIABILITIES (AOP 067+090+097+109+124)	125	273,682,016	302,642,006
G OFF-BALANCE ENTRIES	126	18,603,628	22,715,746

INCOME STATEMENT
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL GROUP

Position name 1	AOP marking 2	Same period previous year 3	Current period 4
I. BUSINESS REVENUE (AOP 002 to 006)	001	104,165,542	126,072,885
1 Sales revenue from enterprises within the group	002	0	0
2 Sales revenue (outside the group)	003	102,355,916	125,156,081
3 Revenue based on use of own products, goods and services	004	0	0
4 Other business revenue from enterprises within the group	005	0	0
5 Other business revenue (outside the group)	006	1,809,626	916,804
II. OPERATING EXPENSES (AOP 08+009+013+017+018+019+022+029)	007	84,408,083	105,942,844
1 Changes in the value of work in progress and finished goods inventory	008	-5,787,644	766,151
2 Material costs (AOP 010 to 012)	009	61,909,195	68,875,555
a) Costs of raw materials	010	23,522,514	24,719,872
b) Costs of sold goods	011	20,019,715	23,467,589
c) Other external costs	012	18,366,966	20,688,094
3 PERSONNEL COSTS (AOP 014 to 016)	013	15,314,293	18,409,665
a) Net wages and salaries	014	9,551,710	11,431,087
b) Costs of taxes and contributions from salary	015	3,374,771	4,249,389
c) Contributions on salary	016	2,387,812	2,729,189
4 Depreciation	017	4,795,965	5,712,557
5 Other costs	018	3,622,652	7,894,882
6 VALUE ADJUSTMENTS (AOP 020+021)	019	1,200,000	371,402
A) non-current assets other than financial assets	020	1,200,000	0
B) current assets other than financial assets	021	0	371,402
7 Provisions (AOP 023 to 028)	022	2,217,333	2,347,154
a) Provisions for retirement, severance and similar liabilities	023	2,217,333	2,347,154
b) Provisions for tax liabilities	024	0	0
c) Provisions for initiated court disputes	025	0	0
d) Provisions for costs of regenerating natural resources	026	0	0
e) Provisions for costs in warranty period	027	0	0
f) Other provisions	028	0	0
8 Other operating expenses	029	1,136,289	1,565,478
III. FINANCIAL REVENUE (AOP 031 to 040)	030	797,190	1,562,619
1 Revenue from investment in shares (stocks) of enterprises within the group	031	0	0
2 Revenue from investment in shares (stocks) of companies connected with participating interests	032	0	0

INCOME STATEMENT
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL GROUP

Position name 1	AOP marking 2	Same period previous year 3	Current period 4
3 Revenue from other long-term financial investments and loans to enterprises within the group	033	0	0
4 Other revenue based on interest rate relating to enterprises within the group	034	0	0
5 Exchange rate differences and other finance from relationship with enterprises within the group	035	0	0
6 Revenue from other long-term financial investments and loans	036	0	0
7 Other revenue based on interest rate	037	78,251	626,974
8 Exchange rate differences and other finance revenue	038	669,331	926,340
9 Unrealized profit (revenue) from financial assets	039	41,301	0
10 Other financial revenue	040	8,307	9,305
IV. FINANCIAL EXPENSES (AOP 042 to 048)	041	5,312,782	1,592,637
1 Expenses based on interest rates and similar expenses with enterprises within the group	042	0	0
2 Exchange rate differences and other expenses of enterprises within the group	043	0	0
3 Expenses based on interest rates and similar expenses	044	852,764	1,137,465
4 Exchange rate differences and other expenses	045	4,460,018	425,724
5 Unrealized losses (expenses) from financial assets	046	0	29,448
6 Value adjustment of financial assets (net)	047	0	0
7 Other finance expenses	048	0	0
V. SHARE IN PROFIT FROM COMPANIES CONNECTED WITH PARTICIPATING INTERESTS	049	0	1,118
VI. SHARE IN PROFIT FROM JOINT VENTURES	050	0	0
VII. SHARE IN LOSS FROM COMPANIES CONNECTED WITH PARTICIPATING INTERESTS*	051	0	0
VIII. SHARE IN LOSS FROM JOINT VENTURES	052	0	0
IX. TOTAL REVENUE (AOP 001+030+049+050)	053	104,962,732	127,636,622
X. TOTAL EXPENSES (AOP 007+041+051+ 052)	054	89,720,865	107,535,481
XI. PROFIT OR LOSS BEFORE TAX (AOP 053-054)	055	15,241,867	20,101,141
1 Profit before tax (AOP 053-054)	056	15,241,867	20,101,141
2 Loss before tax (AOP 054-053)	057	0	0
XII. CORPORATE INCOME TAX	058	0	0
XIII. PROFIT OR LOSS PERIODS (AOP 055-059)	059	15,241,867	20,101,141
1 Profit periods (AOP 055-059)	060	15,241,867	20,101,141
2 Loss periods (AOP 059-055)	061	0	0

INCOME STATEMENT
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL GROUP

Position name	AOP marking	Same period previous year	Current period
1	2	3	4
CEASE OPERATIONS (filled out by undertaking of IFRS payer only if operations ceased)			
XIV. PROFIT OR LOSS OF CEASED OPERATIONS BEFORE TAX (AOP 063-064)	062	0	0
1 Profit of ceased operations before tax	063	0	0
2 Loss of ceased operations before tax	064	0	0
XV. INCOME TAX OF CEASED OPERATIONS	065	0	0
1 Profit of ceased operations for period (AOP 062-065)	066	0	0
2 Loss of ceased operations for period (AOP 065-062)	067	0	0
TOTAL OPERATIONS (filled out only by undertaking of IFRS payer whose operations ceased)			
XVI. PROFIT OR LOSS BEFORE TAX (AOP 055+062)	068	0	
1 Profit before tax (AOP 068)	069	0	0
2 Loss before tax (AOP 068)	070	0	0
XVII. INCOME TAX (AOP 058+065)	071	0	0
XVIII. PROFIT OR LOSS PERIODS (AOP 068-071)	072	0	0
1 Profit periods (AOP 068-071)	073	0	0
2 Loss periods (AOP 071-068)	074	0	0
ADDITION TO THE PROFIT AND LOSS ACCOUNT (to be filled out by the company preparing the consolidated annual financial statement)			
XIX. PROFIT OR LOSS PERIODS (AOP 076+077)	075	0	0
1 Attributable to equity holders of the parent company	076	0	0
2 Assigned to minority (non-controlling) interest	077	0	0
REPORT ON OTHER COMPREHENSIVE INCOME (to be filled out by the company subject to IFRS application)			
I. PROFIT OR LOSS FOR THE PERIOD	078	15,241,867	20,101,141
II. OTHER COMPREHENSIVE PROFIT/LOSS BEFORE TAX (AOP 80+87)	079	-257,400	128,736
III. Items that will not be reclassified to profit or loss (AOP 081 to 085)	080	0	0
1 Changes in revaluation reserves of long-term tangible and intangible assets	081	0	0
2 Profit or loss based on subsequent valuation of securities at fair value through other comprehensive income	082	0	0

INCOME STATEMENT
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL GROUP

Position name 1	AOP marking 2	Same period previous year 3	Current period 4
3 Changes to fair value of financial liability at fair value through income statement which can be assigned to changes to credit risk liability	083	0	0
4 Actuarial gain/loss on defined benefit schemes	084	0	0
5 Other items which will not be reclassified	085	0	0
6 Income tax which relates to items which will not be reclassified	086	0	0
IV. Items which can be reclassified to profit or loss (AOP 088 to 095)	087	-257,400	128,736
1 Exchange differences on translation of foreign operations	088	-257,400	128,736
2 Profit or loss based on subsequent valuation of debt securities at fair value through other comprehensive income	089	0	0
4 Profit or loss based on efficient cash flow protection	090	0	0
5 Profit or loss from effective protection of net foreign investments	091	0	0
6 Share in other comprehensive profit/loss of companies connected with participating interests	092	0	0
6 Changes to fair value of time value option	093	0	0
7 Changes to fair value of time element of futures contracts	094	0	0
8 Other items which can be reclassified into profit or loss	095	0	0
9 Income tax which relates to items which can be reclassified into profit or loss	096	0	0
V. NET OTHER COMPREHENSIVE PROFIT OR LOSS (AOP 080+087 - 086 - 096)	097	-257,400	128,736
VI. COMPREHENSIVE PROFIT OR LOSS PERIODS (AOP 078+097)	098	14,984,467	20,229,877
ADDENDUM to report on other comprehensive profit (filled out by entrepreneur who is preparing a consolidated statement)			
VI. COMPREHENSIVE PROFIT OR LOSS PERIODS (AOP 100+101)	099	14,984,467	20,229,876
1 Attributable to equity holders of the parent company	100	14,984,467	20,229,876
2 Assigned to minority (non-controlling) interest	101	0	0

STATEMENT OF CASH FLOWS – DIRECT METHOD
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL GROUP

Position name	AOP marking	Same period previous year	Current period
1	2	3	4
Cash flows from operating activities			
1 Cash inflow from customers	001	106,166,814	127,565,788
2 Cash inflow from royalties, fees, commissions and similar	002	0	0
3 Cash inflow from damage compensation based on insurance	003	156,908	288,673
4 Cash inflow from tax refund	004	2,020,350	1,808,569
5 Other cash inflow from operating activities	005	288,856	414,401
I. Total cash inflow from operating activities (AOP 001 do 005)	006	108,632,928	130,077,431
1 Cash outflow for suppliers	007	-74,215,325	-82,170,116
2 Cash outflow for employees	008	-12,421,146	-15,202,532
3 Cash outflow from damage compensation based on insurance	009	-171,708	-332,103
4 Cash outflow for interest	010	-589,691	-783,277
5 Paid income tax	011	-132,084	-197,523
6 Other cash outflow from operating activities	012	-14,753,453	-16,883,054
II. Total cash outflow from operating activities (AOP 007 do 012)	013	-102,283,407	-115,568,605
A NET CASH FLOWS FROM OPERATING ACTIVITIES (AOP 006+013)	014	6,349,521	14,508,826
Cash flows from investment activities			
1 Cash inflow from the sale of long-term tangible and intangible assets	015	89,423	167,714
2 Cash inflow from sale of financial instruments	016	0	0
3 Cash inflow from interest	017	89,692	568,650
4 Cash inflow from dividends	018	0	0
5 Cash inflow from refund of loans and savings roles	019	24,816	8,200
6 Other cash inflow from investment activities	020	8,307	9,305
III. Total cash inflow from investment activities (AOP 015 to 020)	021	212,238	753,869
1 Cash outflow for the purchase of long-term tangible and intangible assets	022	-9,560,159	-3,318,512
2 Cash outflow for acquiring financial instruments	023	0	0
3 Cash outflow from loans and savings roles	024	-2,648,579	0
4 Acquiring subsidiary, reduced for acquired money	025	0	0
5 Other cash outflow from investment activities	026	-200,000	-450,000
IV. Total cash outflow from investment activities (AOP 022 to 026)	027	-12,408,738	-3,768,512
B NET CASH FLOWS FROM INVESTMENT ACTIVITIES (AOP 021+027)	028	-12,196,500	-3,014,643

STATEMENT OF CASH FLOWS – DIRECT METHOD
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL GROUP

Position name 1	AOP marking 2	Same period previous year 3	Current period 4
Cash flows from financial activities			
1 Cash inflow from increase of (subscribed) share capital	029	276,510	274,352
2 Cash inflow from issuing equity and debt financial instruments	030	1,609,287	1,899,993
3 Cash inflow from loan principal, borrowings and other lending	031	13,273,437	4,090,154
4 Other cash inflow from financing activities	032	1,779,052	3,151
V. Total cash inflow from financial activities (AOP 029 to 032)	033	16,938,286	6,267,650
1 Cash outflow for payment of loan principal, borrowings and other lending and financial debt instruments	034	-2,393,505	-1,953,477
2 Cash outflow for the payment of dividends	035	-3,558,942	-4,884,804
3 Cash outflow for finance lease	036	-1,424,173	-1,181,676
4 Cash outflow for repurchase of own shares and reduction of (subscribed) share capital	037	-1,773	0
5 Other cash outflow from financial activities	038	0	0
VI. Total cash outflow from financial activities (AOP 034 to 038)	039	-7,378,393	-8,019,957
C NET CASH FLOWS FROM FINANCIAL ACTIVITIES (AOP 033+039)	040	9,559,893	-1,752,307
1 Unrealised cash exchange differences and cash equivalents	041	-38,089	5,961
D NET INCREASE OR REDUCTION OF CASH FLOWS (AOP 014+028+040+041)	042	3,674,825	9,747,837
E CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	043	14,410,215	20,890,800
F CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD (AOP 042+043)	044	18,085,040	30,638,637

STATEMENT OF CHANGES IN EQUITY
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL GROUP

Position description	AOP marking	DIVIDEABLE AMONG HOLDERS OF PARENT COMPANY CAPITAL																	Minority (non-controlling) interest	Total capital and reserves
		(Subscribed) share capital	Capital reserves	Legal reserves	Reserves for own shares	Own shares and interests (deductible item)	Statutory reserves	Other reserves	Revaluation reserves	Fair value of financial assets through other comprehensive income (available for sale)	Efficient part of cash flow protection	Efficient part of net investment abroad protection	Other fair value reserves	Exchange differences on translation of foreign operations	Profit/loss brought forward	Business year profit/loss	Total dividable among holders of parent company capital			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18 (3 do 6 - 7 + 8 do 17)	19	20 (18+19)	
PREVIOUS PERIOD																				
1	Status as at start of previous business year	01	16,374,743	4,691,017	6,869,907	1,003,444	864,981	0	284,130	0	0	0	0	0	175,251	72,664,667	19,203,297	120,401,475	0	120,401,475
2	Accounting policies changes	02	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3	Error correction	03	0	0	0	0	0	0	-6,113	0	0	0	0	0	0	0	6,113	0	0	0
4	Status as at start of previous business year (restated) (AOP 01 to 03)	04	16,374,743	4,691,017	6,869,907	1,003,444	864,981	0	278,017	0	0	0	0	0	175,251	72,664,667	19,209,410	120,401,475	0	120,401,475
5	Profit/loss period	05	0	0	0	0	0	0	0	0	0	0	0	0	0	0	15,241,867	15,241,867	0	15,241,867
6	Exchange differences on translation of foreign operations	06	0	0	0	0	0	0	0	0	0	0	0	-257,400	0	0	-257,400	0	-257,400	
7	Changes in revaluation reserves of long-term tangible and intangible assets	07	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8	Profit or loss based on subsequent valuation of financial assets toward fair value through other comprehensive income (available for sale)	08	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9	Profit or loss based on efficient cash flow protection	09	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	Profit or loss based on efficient net abroad investment protection	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
11	Share in other comprehensive profit/loss of companies connected with participating interests	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12	Actuarial gain/loss on defined benefit schemes	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
13	Other non-equity capital changes	13	-335,928	318,178	0	17,750	0	0	6,113	0	0	0	0	0	0	-6,113	0	0	0	0
14	Transaction tax recognized directly in capital	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
15	Reduction of (subscribed) share capital (other than in pre-bankruptcy settlement proceedings and capital accrued through reinvesting profit)	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16	Reduction of (subscribed) share capital in pre-bankruptcy settlement proceedings	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17	Reduction of (subscribed) share capital accrued through reinvesting profit	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
18	Purchase of own stocks/shares	18			0	-333,983	-333,983	0	0	0	0	0	0	0	0	2,156,743	0	2,156,743	0	2,156,743
19	Member/shareholder payments	19	276,510	1,609,287	0	0	0	0	0	0	0	0	0	0	0	0	0	1,885,797	0	1,885,797
20	Payment of share in profit/dividends	20	0	0	0	0	0	0	0	0	0	0	0	0	-3,582,339	0	-3,582,339	0	-3,582,339	
21	Other distributions and payments to members/shareholders	21	0	0	0	0	0	0	0	0	0	0	0	0	-427,037	0	-427,037	0	-427,037	
22	Transfer into the reserves part according to yearly schedule	22	0		4,717,948	0	0	0	0	0	0	0	0	0	14,491,462	-19,209,410	0	0	0	0
23	Increase of reserves in pre-bankruptcy settlement proceedings	23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
24	Status as at last day of reporting period for previous business year (04 to 23)	24	16,315,325	6,618,482	11,587,855	687,211	530,998	0	284,130	0	0	0	0	0	-82,149	85,297,383	15,241,867	135,419,106	0	135,419,106
ADDENDUM TO STATEMENT ON CHANGES IN EQUITY (filled out by undertaking IFRS payer)																				
I.	OTHER COMPREHENSIVE PROFIT FOR PREVIOUS PERIOD, REDUCED BY TAX (AOP 06 to 14)	25	-335,928	318,178	0	17,750	0	0	6,113	0	0	0	0	0	-257,400	-6,113	0	-257,400	0	-257,400
II.	COMPREHENSIVE PROFIT OR LOSS FOR PREVIOUS PERIOD (AOP 05+25)	26	-335,928	318,178	0	17,750	0	0	6,113	0	0	0	0	0	-257,400	-6,113	15,241,867	14,984,467	0	14,984,467

STATEMENT OF CHANGES IN EQUITY
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL GROUP

Position description	AOP marking	DIVIDEABLE AMONG HOLDERS OF PARENT COMPANY CAPITAL																	Minority (non-controlling) interest	Total capital and reserves
		(Subscribed) share capital	Capital reserves	Legal reserves	Reserves for own shares	Own shares and interests (deductible item)	Statutory reserves	Other reserves	Revaluation reserves	Fair value of financial assets through other comprehensive income (available for sale)	Efficient part of cash flow protection	Efficient part of net investment abroad protection	Other fair value reserves	Exchange differences on translation of foreign operations	Profit/loss brought forward	Business year profit/loss	Total dividable among holders of parent company capital			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18 (3 do 6 - 7 + 8 do 17)	19	20 (18+19)	
III. TRANSACTIONS RELATING TO OWNERS FOR PREVIOUS PERIOD RECOGNIZED DIRECTLY IN CAPITAL (AOP 15 to 23)	27	276,510	1,609,287	4,717,948	-333,983	-333,983	0	0	0	0	0	0	0	0	12,638,829	-19,209,410	33,164	0	33,164	
CURRENT PERIOD																				
1 Status as at start of current business year	28	16,315,325	6,618,482	11,587,855	688,771	532,558	0	278,017	0	0	0	0	0	-278,088	85,174,931	19,582,473	139,435,208	0	139,435,208	
2 Accounting policies changes	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
3 Error correction	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
4 Status as at start of current business year (re-stated) (AOP 28 to 30)	31	16,315,325	6,618,482	11,587,855	688,771	532,558	0	278,017	0	0	0	0	0	-278,088	85,174,931	19,582,473	139,435,208	0	139,435,208	
5 Profit/loss period	32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	20,101,141	20,101,141	0	20,101,141	
6 Exchange differences on translation of foreign operations	33	0	0	0	0	0	0	0	0	0	0	0	0	128,736	0	0	128,736	0	128,736	
7 Changes in revaluation reserves of long-term tangible and intangible assets	34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
8 Profit or loss based on subsequent valuation of financial assets toward fair value through other comprehensive income (available for sale)	35	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
9 Profit or loss based on efficient cash flow protection	36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
10 Profit or loss based on efficient net abroad investment protection	37	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
11 Share in other comprehensive profit/loss of companies connected with participating interests	38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
12 Actuarial gain/loss on defined benefit schemes	39	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
13 Other non-equity capital changes	40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
14 Transaction tax recognized directly in capital	41	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
15 Reduction of (subscribed) share capital (other than in pre-bankruptcy settlement proceedings and capital accrued through reinvesting profit)	42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
16 Reduction of (subscribed) share capital in pre-bankruptcy settlement proceedings	43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
17 Reduction of (subscribed) share capital accrued through reinvesting profit	44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
18 Purchase of own stocks/shares	45	0	0	0	-63,635	-63,635	0	0	0	0	0	0	0	0	504,332	0	504,332	0	504,332	
19 Member/shareholder payments	46	274,352	1,899,993	0	0	0	0	0	0	0	0	0	0	0	0	0	2,174,345	0	2,174,345	
20 Payment of share in profit/dividends	47	0	0	0	0	0	0	0	0	0	0	0	0	-4,960,232	0	-4,960,232	0	-4,960,232		
21 Other distributions and payments to members/shareholders	48	0	0	0	0	0	0	0	0	0	0	0	0	83,887	0	83,887	0	83,887		
22 Transfer according to yearly schedule	49	0	0	0	0	0	0	0	0	0	0	0	0	19,582,473	-19,582,473	0	0	0		
23 Increase of reserves in pre-bankruptcy settlement proceedings	50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
24 Status as at last day of reporting period for current business year (AOP 31 to 50)	51	16,589,677	8,518,475	11,587,855	625,136	468,923	0	278,017	0	0	0	0	0	-149,352	100,385,391	20,101,141	157,467,417	0	157,467,417	
ADDENDUM TO STATEMENT ON CHANGES IN EQUITY (filled out by undertaking IFRS payer)																				
I. OTHER COMPREHENSIVE PROFIT FOR CURRENT PERIOD, REDUCED BY TAX (AOP 33 to 41)	52	0	0	0	0	0	0	0	0	0	0	0	0	128,736	0	0	128,736	0	128,736	
II. COMPREHENSIVE PROFIT OR LOSS FOR CURRENT PERIOD (AOP 32+52)	53	0	0	0	0	0	0	0	0	0	0	0	0	128,736	0	20,101,141	20,229,877	0	20,229,877	
III. TRANSACTIONS RELATING TO OWNERS FOR CURRENT PERIOD RECOGNIZED DIRECTLY IN CAPITAL (AOP 42 to 50)	54	274,352	1,899,993	0	-63,635	-63,635	0	0	0	0	0	0	0	0	15,210,460	-19,582,473	-2,197,668	0	-2,197,668	

NOTES ACCOMPANYING FINANCIAL STATEMENTS – PFI

(created for the semi-annual period)

ISSUER NAME:	JGL d.d.
PIN (OIB):	20950636972
REPORTING PERIOD:	01.01.-30.06.2024.

Notes to financial statements for semi-annual periods include:

- a. explanation of business events relevant to understanding changes in the statement of financial position and financial performance for the reporting semi-annual period of the issuer with respect to the last business year: information is provided regarding these events and relevant information published in the last annual financial statement is updated (items 15 to 15C IAS 34 - Interim financial reporting)
All explanations are included in the Semi-annual management report.
- b. information on the access to the latest annual financial statements, for the purpose of understanding information published in the notes to financial statements drawn up for the semi-annual reporting period
The latest annual reports are available on the ZSE website and at <https://www.jgl.hr/o-jgl-u/financij-ski-izvjestaji>
- c. a statement explaining that the same accounting policies are applied while drawing up financial statements for the semi-annual reporting period as in the latest annual financial statements or, in the case where the accounting policies have changed, a description of the nature and effect of the changes (item 16.A (a) IAS 34 - Interim financial reporting)
The same accounting policies as for the annual financial statements for the year 2023 are applied for the preparation of these semi-annual reports.
- d. a description of the financial performance in the case of the issuer whose business is seasonal (items 37 and 38 IAS 34 - Interim financial reporting)
The group does not perform activities of a seasonal nature.
- e. other comments prescribed by IAS 34 - Interim financial reporting
- f. in the notes to the semi-annual financial state-

ments, in addition to the information stated above, information in respect of the following matters shall be disclosed:

1. undertaking's name, registered office (address), legal form, country of establishment, entity's registration number and, if applicable, the indication whether the undertaking is undergoing liquidation, bankruptcy proceedings, shortened termination proceedings or extraordinary administration
JGL d.d., Rijeka, Svilno 20., country of incorporation Croatia, other information can be found in the General Information sheet and in the Semi - annual management report.
2. adopted accounting policies (only an indication of whether there has been a change from the previous period)
There were no changes in accounting policies during 2024.
3. the total amount of any financial commitments, guarantees or contingencies that are not included in the balance sheet, and an indication of the nature and form of any valuable security which has been provided; any commitments concerning pensions of the undertaking within the group or company linked by virtue of participating interest shall be disclosed separately
This information is included in the Semi-annual management report.
4. the amount and nature of individual items of income or expenditure which are of exceptional size or incidence
Individual income items of exceptional size are explained in the Semi - annual management report. Items of exceptional size of expenditure are Direct costs of raw materials and materials amounting to EUR 23,151,193 or 22% of total expenditure, costs of purchase value of goods sold amounting to EUR 23,467,589 or 22% and staff costs amounting to EUR 18,409,665 or 17%.
5. amounts owed by the undertaking and falling due after more than five years, as well as the total debts of the undertaking covered by valuable security furnished by the undertaking, specifying the type and form of security
Of the total long-term liabilities in the amount of

- EUR 68,201,723, liabilities with a term longer than 5 years account for EUR 27,416,799, namely leases EUR 504,925, loans EUR 26,144,804 and deferred tax liabilities in the amount of EUR 767,071.
6. average number of employees during the financial year
The average number of employees in the group in the period is 1310.
 7. where, in accordance with the regulations, the undertaking capitalised on the cost of salaries in part or in full, information on the amount of the total cost of employees during the year broken down into the amount directly debiting the costs of the period and the amount capitalised on the value of the assets during the period, showing separately the total amount of net salaries and the amount of taxes, contributions from salaries and contributions on salaries
In the Profit and loss statement, salary expenses less capitalized amounts are shown, namely net salary in the amount of EUR 134,506, taxes and salary contributions in the amount of EUR 56,973 and salary contributions in the amount of EUR 25,669.
 8. where a provision for deferred tax is recognised in the balance sheet, the deferred tax balances at the end of the financial year, and the movement in those balances during the financial year
In the observed period, deferred tax assets increased by EUR 552,309, while deferred tax liabilities increased by EUR 642,915.
 9. the name and registered office of each of the undertakings in which the undertaking, either itself or through a person acting in their own name but on the undertaking's behalf, holds a participating interest, showing the proportion of the capital held, the amount of capital and reserves, and the profit or loss for the latest financial year of the undertaking concerned for which financial statements have been adopted; the information concerning capital and reserves and the profit or loss may be omitted where the undertaking concerned does not publish its balance sheet and is not controlled by another undertaking
In the Management Report, all members of the JGL Group are listed, and their ownership structure is described.
 10. the number and the nominal value or, in the absence of a nominal value, the accounting par value of the shares subscribed during the financial year within the limits of the authorised capital
JGL d.d. increased the share capital by 21,104 new shares at a nominal value of EUR 13.00 on April 25, 2024.
 11. the existence of any participation certificates, convertible debentures, warrants, options or similar securities or rights, with an indication of their number and the rights they confer
There were no such participations or transactions.
the name, registered office and legal form of each of the undertakings of which the undertaking is a member having unlimited liability
 12. the name, registered office and legal form of each of the undertakings of which the undertaking is a member having unlimited liability
JGL d.d. has unlimited responsibility in every company of the Group.
 13. the name and registered office of the undertaking which draws up the consolidated financial statements of the largest group of undertakings of which the undertaking forms part as a controlled group member
JGL d.d. is the parent member of the group and is not a controlled member of any Group.
 14. the name and registered office of the undertaking which draws up the consolidated financial statements of the smallest group of undertakings of which the undertaking forms part as a controlled group member and which is also included in the group of undertakings referred to in point 13
JGL d.d. is the only one that compiles a half-yearly consolidated report.
 15. the place where copies of the consolidated financial statements referred to in points 13 and 14 may be obtained, provided that they are available
Not applicable.
 16. the nature and business purpose of the undertaking's arrangements that are not included in the balance sheet and the financial impact on the undertaking of those arrangements, provided that the risks or benefits arising from such arrangements are material and in so far as the disclosure of such risks or benefits is necessary for the purposes of assessing the financial position of the undertaking
Not applicable.
 17. the nature and the financial effect of material events arising after the balance sheet date which are not reflected in the profit and loss account or balance sheet
After the balance sheet date, the share capital was paid into the new subsidiary JADRAN Kazakhstan LLP, while ZU "Goranske ljekarna" was legally merged with ZU "Ljekarna Pablo". The financial effects are not significant.

Financial Reports JGL d.d.

78	Balance sheet
82	Income statement
86	Statement of cash flows – direct method
88	Statement of changes in equity
90	Notes accompanying financial statements – PFI

BALANCE SHEET
 Status as at 30/06/2024
 In euros

Company:
 JGL d.d.

Position name	AOP marking	Last day of previous business year	As at reporting date of current period
1	2	3	4
ASSETS			
A RECEIVABLES FOR REGISTERED BUT UNPAID CAPITAL	001	0	0
B NON-CURRENT ASSETS (AOP 003+010+020+031+036)	002	149,292,414	148,350,886
I. INTANGIBLE ASSETS (AOP 004 to 009)	003	17,017,769	18,114,334
1 Development costs	004	3,077,481	2,920,432
2 Concessions, patents, licences, brand and service name, software and other rights	005	3,824,410	3,695,926
3 Goodwill	006	0	0
4 Advance payments for the procurement of intangible assets	007	0	0
5 Intangible assets in preparation	008	7,973,226	9,425,509
6 Other intangible assets	009	2,142,652	2,072,467
II. TANGIBLE ASSETS (AOP 011 to 019)	010	110,791,778	108,592,435
1 Land	011	5,820,536	5,820,536
2 Buildings	012	47,870,746	47,264,273
3 Plants and equipment	013	49,926,791	48,156,589
4 Tools, plant inventory and transportation assets	014	3,224,996	3,222,146
5 Biological assets	015	0	0
6 Advance payments for tangible assets	016	0	0
7 Tangible assets in preparation	017	1,445,695	1,624,279
8 Other tangible assets	018	165,272	166,870
9 Investment property	019	2,337,742	2,337,742
III. NON-CURRENT FINANCIAL ASSETS (AOP 021 to 030)	020	18,655,630	18,816,880
1 Investment in shares (stocks) of enterprises within the group	021	18,492,172	18,653,422
2 Investment in other securities of enterprises within the group	022	0	0
3 Loans granted, deposits and similar to enterprises within the group	023	0	0
4 Investment in shares (stocks) of companies connected with participating interests	024	6,503	6,503
5 Investment in other securities of companies connected with participating interests	025	0	0
6 Loans granted, deposits and similar to companies connected with participating interests	026	0	0
7 Investments in securities	027	156,955	156,955
8 Given loans, deposits and similar	028	0	0
9 Other investments calculated using the equity method	029	0	0
10 Other long-term financial assets	030	0	0
IV. RECEIVABLES (AOP 032 to 035)	031	0	0
1 Receivables of enterprises within the group	032	0	0

BALANCE SHEET
Status as at 30/06/2024
In euros

Company:
JGL d.d.

Position name 1	AOP marking 2	Last day of previous business year 3	As at reporting date of current period 4
2 Receivables of companies connected with participating interests	033	0	0
3 Trade receivables	034	0	0
4 Other receivables	035	0	0
V. DEFERRED TAX ASSETS	036	2,827,237	2,827,237
C CURRENT ASSETS (AOP 038+046+053+063)	037	100,232,840	113,938,936
I. INVENTORIES (AOP 039 to 045)	038	40,659,521	47,660,653
1 Raw materials	039	18,373,091	24,694,101
2 Work in progress	040	776	309,538
3 Finished goods	041	16,275,765	14,465,683
4 Trade goods	042	6,009,889	8,191,331
5 Advance payments for inventory	043	0	0
6 Long-term assets intended for sale	044	0	0
7 Biological assets	045	0	0
II. RECEIVABLES (AOP 047 to 052)	046	40,058,045	37,914,934
1 Receivables of enterprises within the group	047	21,388,021	13,635,479
2 Receivables of companies connected with participating interests	048	0	0
3 Trade receivables	049	16,749,203	22,677,621
4 Receivables from employees and company members	050	16,405	106,522
5 Receivables from the Government and other institutions	051	1,164,230	921,672
6 Other receivables	052	740,186	573,640
III. CURRENT FINANCIAL ASSETS (AOP 054 to 062)	053	2,967,905	2,930,839
1 Investment in shares (stocks) of enterprises within the group	054	0	0
2 Investment in other securities of enterprises within the group	055	0	0
3 Loans granted, deposits and similar to enterprises within the group	056	18,100	18,683
4 Investment in shares (stocks) of companies connected with participating interests	057	0	0
5 Investment in other securities of companies connected with participating interests	058	0	0
6 Loans granted, deposits and similar to companies connected with participating interests	059	0	0
7 Investments in securities	060	0	0
8 Given loans, deposits and similar	061	30,000	21,800
9 Other financial assets	062	2,919,805	2,890,356
IV. CASH AT BANK AND IN HAND	063	16,547,369	25,432,510
D PREPAID EXPENSES AND ACCRUED REVENUE	064	821,074	624,350
E TOTAL ASSETS (AOP 001+002+037+064)	065	250,346,328	262,914,172
F IZVANBILANČNI ZAPISI	066	18,603,628	22,699,292

BALANCE SHEET
 Status as at 30/06/2024
 In euros

Company:
 JGL d.d.

Position name	AOP marking	Last day of previous business year	As at reporting date of current period
1	2	3	4
LIABILITIES			
A CAPITAL AND RESERVES	067	136,904,225	144,985,027
(AOP 068 to 070+076+077+083+086+089)			
I. SHARE (SUBSCRIBED) CAPITAL	068	16,315,325	16,589,677
II. CAPITAL RESERVES	069	6,618,482	8,518,476
III. PROFIT RESERVES (AOP 071+072-073+074+075)	070	12,022,085	12,022,086
1 Legal reserves	071	11,587,855	11,587,855
2 Reserves for own shares	072	688,771	625,137
3 Own shares and interests (deductible item)	073	-532,558	-468,923
4 Statutory reserves	074	0	0
5 Other reserves	075	278,017	278,017
IV. REVALUATION RESERVES	076	0	0
V. FAIR VALUE RESERVES AND OTHER (AOP 078 to 082)	077	0	0
1 Fair value of financial assets through other comprehensive income (in other words, available for sale)	078	0	0
2 Efficient part of cash flow protection	079	0	0
3 Efficient part of net abroad investment protection	080	0	0
4 Other fair value reserves	081	0	0
5 Foreign exchange gains/losses from conversion of operations abroad (consolidation)	082	0	0
VI. PROFIT OR LOSS BROUGHT FORWARD (AOP 084-085)	083	88,863,597	97,492,433
1 Profit brought forward	084	88,863,597	97,492,433
2 Loss brought forward	085	0	0
VII. BUSINESS YEAR PROFIT OR LOSS (AOP 087-088)	086	13,084,736	10,362,355
1 Profit for the financial year	087	13,084,736	10,362,355
2 Loss for the financial year	088	0	0
VIII. MINORITY (NON-CONTROLLING) INTEREST	089	0	0
B PROVISIONS (AOP 091 to 096)	090	472,073	472,073
1 Provisions for pensions, severances and similar obligations	091	373,865	373,865
2 Provisions for taxation	092	0	0
3 Provisions for initiated court disputes	093	98,208	98,208
4 Provisions for costs of regenerating natural resources	094	0	0
5 Provisions for costs in warranty period	095	0	0
6 Other provisions	096	0	0

BALANCE SHEET
Status as at 30/06/2024
In euros

Company:
JGL d.d.

Position name	AOP marking	Last day of previous business year	As at reporting date of current period
1	2	3	4
C LONG-TERM LIABILITIES (AOP 098 to 108)	097	61,971,467	62,210,760
1 Liabilities towards enterprises within the group	098	0	0
2 Liabilities for loans, deposits and similar for enterprises within the group	099	0	0
3 Liabilities towards companies connected with participating interests	100	0	0
4 Liabilities for loans, deposits and similar to companies connected with participating interests	101	0	0
5 Liabilities for loans, deposits and similar	102	0	0
6 Liabilities towards banks and other financial institutions	103	61,971,242	62,210,535
7 Liabilities for advance payments	104	0	0
8 Trade payables	105	225	225
9 Liabilities arising from securities	106	0	0
10 Other long-term liabilities	107	0	0
11 Deferred tax liability	108	0	0
D SHORT-TERM LIABILITIES (AOP 110 to 123)	109	48,898,458	53,302,116
1 Liabilities towards enterprises within the group	110	516,236	647,295
2 Liabilities for loans, deposits and similar for enterprises within the group	111	0	0
3 Liabilities towards companies connected with participating interests	112	0	0
4 Liabilities for loans, deposits and similar to companies connected with participating interests	113	0	0
5 Liabilities for loans, deposits and similar	114	0	0
6 Liabilities towards banks and other financial institutions	115	6,640,374	4,470,198
7 Liabilities for advance payments	116	101,884	0
8 Trade payables	117	18,107,652	29,112,616
9 Liabilities arising from securities	118	16,941,677	16,965,098
10 Liabilities towards employees	119	3,146,274	1,170,362
11 Liabilities for taxes, contributions and similar payments	120	2,678,904	657,073
12 Liabilities due to share in result	121	62,112	137,540
13 Liabilities due to long-term assets intended for sale	122	0	0
14 Other current liabilities	123	703,345	141,934
E ACCRUED EXPENSES AND DEFERRED REVENUE	124	2,100,105	1,944,196
F TOTAL – LIABILITIES (AOP 067+090+097+109+124)	125	250,346,328	262,914,172
G OFF-BALANCE ENTRIES	126	18,603,628	22,699,292

INCOME STATEMENT
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL d.d.

Position name 1	AOP marking 2	Last day of previous business year 3	As at reporting date of current period 4
I. BUSINESS REVENUE (AOP 002 to 006)	001	66,744,359	77,365,716
1 Sales revenue from enterprises within the group	002	23,228,194	23,930,539
2 Sales revenue (outside the group)	003	43,131,941	52,804,129
3 Revenue based on use of own products, goods and services	004	0	0
4 Other business revenue from enterprises within the group	005	9,500	129,065
5 Other business revenue (outside the group)	006	374,724	501,983
II. OPERATING EXPENSES (AOP 08+009+013+017+018+019+022+029)	007	48,986,274	68,103,272
1 Changes in the value of work in progress and finished goods inventory	008	-5,804,991	760,195
2 Material costs (AOP 010 to 012)	009	35,685,631	41,265,790
a) Costs of raw materials	010	22,012,790	22,730,061
b) Costs of sold goods	011	6,895,061	8,695,488
c) Other external costs	012	6,777,780	9,840,241
3 PERSONNEL COSTS (AOP 014 to 016)	013	8,887,065	11,377,222
a) Net wages and salaries	014	5,526,964	7,015,657
b) Costs of taxes and contributions from salary	015	2,220,813	2,917,928
c) Contributions on salary	016	1,139,288	1,443,637
4 Depreciation	017	4,002,628	4,765,600
5 Other costs	018	2,373,292	6,401,881
6 VALUE ADJUSTMENTS (AOP 020+021)	019	1,200,000	207,734
A) non-current assets other than financial assets	020	1,200,000	0
B) current assets other than financial assets	021	0	207,734
7 Provisions (AOP 023 to 028)	022	1,590,321	1,842,277
a) Provisions for retirement, severance and similar liabilities	023	1,590,321	1,842,277
b) Provisions for tax liabilities	024	0	0
c) Provisions for initiated court disputes	025	0	0
d) Provisions for costs of regenerating natural resources	026	0	0
e) Provisions for costs in warranty period	027	0	0
f) Other provisions	028	0	0
8 Other operating expenses	029	1,052,328	1,482,573
III. FINANCIAL REVENUE (AOP 031 to 040)	030	568,791	2,134,464
1 Revenue from investment in shares (stocks) of enterprises within the group	031	0	900,000
2 Revenue from investment in shares (stocks) of companies connected with participating interests	032	0	0

INCOME STATEMENT
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL d.d.

Position name 1	AOP marking 2	Last day of previous business year 3	As at reporting date of current period 4
3 Revenue from other long-term financial investments and loans to enterprises within the group	033	0	0
4 Other revenue based on interest rate relating to enterprises within the group	034	0	0
5 Exchange rate differences and other finance from relationship with enterprises within the group	035	339,295	266,806
6 Revenue from other long-term financial investments and loans	036	0	0
7 Other revenue based on interest rate	037	40,050	411,886
8 Exchange rate differences and other finance revenue	038	139,838	546,467
9 Unrealized profit (revenue) from financial assets	039	41,301	0
10 Other financial revenue	040	8,307	9,305
IV. FINANCIAL EXPENSES (AOP 042 to 048)	041	4,921,560	1,034,553
1 Expenses based on interest rates and similar expenses with enterprises within the group	042	0	0
2 Exchange rate differences and other expenses of enterprises within the group	043	4,012,398	26,876
3 Expenses based on interest rates and similar expenses	044	653,235	698,416
4 Exchange rate differences and other expenses	045	255,927	279,813
5 Unrealized losses (expenses) from financial assets	046	0	29,448
6 Value adjustment of financial assets (net)	047	0	0
7 Other finance expenses	048	0	0
V. SHARE IN PROFIT FROM COMPANIES CONNECTED WITH PARTICIPATING INTERESTS	049	0	0
VI. SHARE IN PROFIT FROM JOINT VENTURES	050	0	0
VII. SHARE IN LOSS FROM COMPANIES CONNECTED WITH PARTICIPATING INTERESTS*	051	0	0
VIII. SHARE IN LOSS FROM JOINT VENTURES	052	0	0
IX. TOTAL REVENUE (AOP 001+030+049+050)	053	67,313,150	79,500,180
X. TOTAL EXPENSES (AOP 007+041+051+ 052)	054	53,907,834	69,137,825
XI. PROFIT OR LOSS BEFORE TAX (AOP 053-054)	055	13,405,316	10,362,355
1 Profit before tax (AOP 053-054)	056	13,405,316	10,362,355
2 Loss before tax (AOP 054-053)	057	0	0
XII. CORPORATE INCOME TAX	058	0	0
XIII. PROFIT OR LOSS PERIODS (AOP 055-059)	059	13,405,316	10,362,355
1 Profit periods (AOP 055-059)	060	13,405,316	10,362,355
2 Loss periods (AOP 059-055)	061	0	0

INCOME STATEMENT
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL d.d.

Position name	AOP marking	Last day of previous business year	As at reporting date of current period
1	2	3	4
CEASE OPERATIONS (filled out by undertaking of IFRS payer only if operations ceased)			
XIV. PROFIT OR LOSS OF CEASED OPERATIONS BEFORE TAX (AOP 063-064)	062	0	0
1 Profit of ceased operations before tax	063	0	0
2 Loss of ceased operations before tax	064	0	0
XV. INCOME TAX OF CEASED OPERATIONS	065	0	0
1 Profit of ceased operations for period (AOP 062-065)	066	0	0
2 Loss of ceased operations for period (AOP 065-062)	067	0	0
TOTAL OPERATIONS (filled out only by undertaking of IFRS payer whose operations ceased)			
XVI. PROFIT OR LOSS BEFORE TAX (AOP 055+062)	068	0	0
1 Profit before tax (AOP 068)	069	0	0
2 Loss before tax (AOP 068)	070	0	0
XVII. INCOME TAX (AOP 058+065)	071	0	0
XVIII. PROFIT OR LOSS PERIODS (AOP 068-071)	072	0	0
1 Profit periods (AOP 068-071)	073	0	0
2 Loss periods (AOP 071-068)	074	0	0
ADDITION TO THE PROFIT AND LOSS ACCOUNT (to be filled out by the company preparing the consolidated annual financial statement)			
XIX. PROFIT OR LOSS PERIODS (AOP 076+077)	075	0	0
1 Attributable to equity holders of the parent company	076	0	0
2 Assigned to minority (non-controlling) interest	077	0	0
REPORT ON OTHER COMPREHENSIVE INCOME (to be filled out by the company subject to IFRS application)			
I. PROFIT OR LOSS FOR THE PERIOD	078	13,405,316	10,362,354
II. OTHER COMPREHENSIVE PROFIT/LOSS BEFORE TAX (AOP 80+87)	079	0	0
III. Items that will not be reclassified to profit or loss (AOP 081 to 085)	080	0	0
1 Changes in revaluation reserves of long-term tangible and intangible assets	081	0	0
2 Profit or loss based on subsequent valuation of securities at fair value through other comprehensive income	082	0	0

INCOME STATEMENT
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL d.d.

Position name 1	AOP marking 2	Last day of previous business year 3	As at reporting date of current period 4
3 Changes to fair value of financial liability at fair value through income statement which can be assigned to changes to credit risk liability	083	0	0
4 Actuarial gain/loss on defined benefit schemes	084	0	0
5 Other items which will not be reclassified	085	0	0
6 Income tax which relates to items which will not be reclassified	086	0	0
IV. Items which can be reclassified to profit or loss (AOP 088 to 095)	087	0	0
1 Exchange differences on translation of foreign operations	088	0	0
2 Profit or loss based on subsequent valuation of debt securities at fair value through other comprehensive income	089	0	0
4 Profit or loss based on efficient cash flow protection	090	0	0
5 Profit or loss from effective protection of net foreign investments	091	0	0
6 Share in other comprehensive profit/loss of companies connected with participating interests	092	0	0
6 Changes to fair value of time value option	093	0	0
7 Changes to fair value of time element of futures contracts	094	0	0
8 Other items which can be reclassified into profit or loss	095	0	0
9 Income tax which relates to items which can be reclassified into profit or loss	096	0	0
V. NET OTHER COMPREHENSIVE PROFIT OR LOSS (AOP 080+087 - 086 - 096)	097	0	0
VI. COMPREHENSIVE PROFIT OR LOSS PERIODS (AOP 078+097)	098	13,405,316	10,362,354
ADDENDUM to report on other comprehensive profit (filled out by entrepreneur who is preparing a consolidated statement)			
VI. COMPREHENSIVE PROFIT OR LOSS PERIODS (AOP 100+101)	099	0	0
1 Attributable to equity holders of the parent company	100	0	0
2 Assigned to minority (non-controlling) interest	101	0	0

STATEMENT OF CASH FLOWS – DIRECT METHOD
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL d.d.

Position name 1	AOP marking 2	Last day of previous business year 3	As at reporting date of current period 4
Cash flows from operating activities			
1 Cash inflow from customers	001	64,638,962	80,334,501
2 Cash inflow from royalties, fees, commissions and similar	002	0	0
3 Cash inflow from damage compensation based on insurance	003	148,927	282,878
4 Cash inflow from tax refund	004	1,920,721	1,668,765
5 Other cash inflow from operating activities	005	46,575	251,130
I. Total cash inflow from operating activities (AOP 001 do 005)	006	66,755,185	82,537,274
1 Cash outflow for suppliers	007	-45,896,897	-49,219,682
2 Cash outflow for employees	008	-7,486,689	-9,528,852
3 Cash outflow from damage compensation based on insurance	009	-156,573	-314,815
4 Cash outflow for interest	010	-578,223	-743,983
5 Paid income tax	011	-22,139	-6,389
6 Other cash outflow from operating activities	012	-6,689,780	-7,427,982
II. Total cash outflow from operating activities (AOP 007 do 012)	013	-60,830,301	-67,241,703
A NET CASH FLOWS FROM OPERATING ACTIVITIES (AOP 006+013)	014	5,924,884	15,295,571
Cash flows from investment activities			
1 Cash inflow from the sale of long-term tangible and intangible assets	015	101,218	167,795
2 Cash inflow from sale of financial instruments	016	0	0
3 Cash inflow from interest	017	51,491	350,970
4 Cash inflow from dividends	018	0	880,000
5 Cash inflow from refund of loans and savings roles	019	174,616	8,200
6 Other cash inflow from investment activities	020	8,307	9,305
III. Total cash inflow from investment activities (AOP 015 to 020)	021	335,632	1,416,270
1 Cash outflow for the purchase of long-term tangible and intangible assets	022	-9,281,093	-2,959,087
2 Cash outflow for acquiring financial instruments	023	0	0
3 Cash outflow from loans and savings roles	024	-2,000	0
4 Acquiring subsidiary, reduced for acquired money	025	0	0
5 Other cash outflow from investment activities	026	0	0
IV. Total cash outflow from investment activities (AOP 022 to 026)	027	-9,283,093	-2,959,087
B NET CASH FLOWS FROM INVESTMENT ACTIVITIES (AOP 021+027)	028	-8,947,461	-1,542,817

STATEMENT OF CASH FLOWS – DIRECT METHOD
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL d.d.

Position name	AOP marking	Last day of previous business year	As at reporting date of current period
1	2	3	4
Cash flows from financial activities			
1 Cash inflow from increase of (subscribed) share capital	029	276,510	274,352
2 Cash inflow from issuing equity and debt financial instruments	030	1,609,287	1,899,993
3 Cash inflow from loan principal, borrowings and other lending	031	10,233,767	0
4 Other cash inflow from financing activities	032	1,779,052	0
V. Total cash inflow from financial activities (AOP 029 to 032)	033	13,898,616	2,174,345
1 Cash outflow for payment of loan principal, borrowings and other lending and financial debt instruments	034	-2,228,164	-1,764,462
2 Cash outflow for the payment of dividends	035	-3,558,942	-4,884,804
3 Cash outflow for finance lease	036	-674,494	-398,652
4 Cash outflow for repurchase of own shares and reduction of (subscribed) share capital	037	-1,773	0
5 Other cash outflow from financial activities	038	0	0
VI. Total cash outflow from financial activities (AOP 034 to 038)	039	-6,463,373	-7,047,918
C NET CASH FLOWS FROM FINANCIAL ACTIVITIES (AOP 033+039)	040	7,435,243	-4,873,573
1 Unrealised cash exchange differences and cash equivalents	041	-38,089	5,960
D NET INCREASE OR REDUCTION OF CASH FLOWS (AOP 014+028+040+041)	042	4,374,577	8,885,141
E CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	043	10,475,852	16,547,369
F CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD (AOP 042+043)	044	14,850,429	25,432,510

STATEMENT OF CHANGES IN EQUITY
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL d.d.

Position description	AOP marking	DIVIDEABLE AMONG HOLDERS OF PARENT COMPANY CAPITAL																	Minority (non-controlling) interest	Total capital and reserves
		(Subscribed) share capital	Capital reserves	Legal reserves	Reserves for own shares	Own shares and interests (deductible item)	Statutory reserves	Other reserves	Revaluation reserves	Fair value of financial assets through other comprehensive income (available for sale)	Efficient part of cash flow protection	Efficient part of net investment abroad protection	Other fair value reserves	Exchange differences on translation of foreign operations	Profit/loss brought forward	Business year profit/loss	Total dividable among holders of parent company capital			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18 (3 do 6 - 7 + 8 do 17)	19	20 (18+19)	
PREVIOUS PERIOD																				
1	Status as at start of previous business year	01	16,374,743	4,691,017	6,869,907	1,003,444	864,981	0	284,130	0	0	0	0	0	0	79,348,611	15,664,780	123,371,651	0	123,371,651
2	Accounting policies changes	02	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3	Error correction	03	0	0	0	0	0	0	-6,113	0	0	0	0	0	0	0	6,113	0	0	0
4	Status as at start of previous business year (restated) (AOP 01 to 03)	04	16,374,743	4,691,017	6,869,907	1,003,444	864,981	0	278,017	0	0	0	0	0	0	79,348,611	15,670,893	123,371,651	0	123,371,651
5	Profit/loss period	05	0	0	0	0	0	0	0	0	0	0	0	0	0	0	13,405,316	13,405,316	0	13,405,316
6	Exchange differences on translation of foreign operations	06	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7	Changes in revaluation reserves of long-term tangible and intangible assets	07	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8	Profit or loss based on subsequent valuation of financial assets toward fair value through other comprehensive income (available for sale)	08	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9	Profit or loss based on efficient cash flow protection	09	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	Profit or loss based on efficient net abroad investment protection	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
11	Share in other comprehensive profit/loss of companies connected with participating interests	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12	Actuarial gain/loss on defined benefit schemes	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
13	Other non-equity capital changes	13	-335,928	318,177	0	17,751	0	0	6,113	0	0	0	0	0	0	-6,113	0	0	0	0
14	Transaction tax recognized directly in capital	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
15	Reduction of (subscribed) share capital (other than in pre-bankruptcy settlement proceedings and capital accrued through reinvesting profit)	15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16	Reduction of (subscribed) share capital in pre-bankruptcy settlement proceedings	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17	Reduction of (subscribed) share capital accrued through reinvesting profit	17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
18	Purchase of own stocks/shares	18	0	0	0	-333,983	-333,983	0	0	0	0	0	0	0	0	2,156,743	0	2,156,743	0	2,156,743
19	Member/shareholder payments	19	276,510	1,609,288	0	0	0	0	0	0	0	0	0	0	0	0	0	1,885,798	0	1,885,798
20	Payment of share in profit/dividends	20	0	0	0	0	0	0	0	0	0	0	0	0	-3,582,339	0	-3,582,339	0	-3,582,339	
21	Other distributions and payments to members/shareholders	21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
22	Transfer into the reserves part according to yearly schedule	22	0	0	4,717,948	0	0	0	0	0	0	0	0	0	0	10,952,945	-15,670,893	0	0	0
23	Increase of reserves in pre-bankruptcy settlement proceedings	23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
24	Status as at last day of reporting period for previous business year (04 to 23)	24	16,315,325	6,618,482	11,587,855	687,212	530,998	0	284,130	0	0	0	0	0	0	88,869,847	13,405,316	137,237,169	0	137,237,169
ADDENDUM TO STATEMENT ON CHANGES IN EQUITY (filled out by undertaking IFRS payer)																				
I.	OTHER COMPREHENSIVE PROFIT FOR PREVIOUS PERIOD, REDUCED BY TAX (AOP 06 to 14)	25	-335,928	318,177	0	17,751	0	0	6,113	0	0	0	0	0	0	-6,113	0	0	0	0
II.	COMPREHENSIVE PROFIT OR LOSS FOR PREVIOUS PERIOD (AOP 05+25)	26	-335,928	318,177	0	17,751	0	0	6,113	0	0	0	0	0	0	-6,113	13,405,316	13,405,316	0	13,405,316
III.	TRANSACTIONS RELATING TO OWNERS FOR PREVIOUS PERIOD RECOGNIZED DIRECTLY IN CAPITAL (AOP 15 to 23)	27	276,510	1,609,288	4,717,948	-333,983	-333,983	0	0	0	0	0	0	0	0	9,527,349	-15,670,893	460,202	0	460,202

STATEMENT OF CHANGES IN EQUITY
for the period from 01/01/2024 to 30/06/2024
in euros

Company:
JGL d.d.

Position description	AOP marking	DIVIDEABLE AMONG HOLDERS OF PARENT COMPANY CAPITAL																	Minority (non-controlling) interest	Total capital and reserves
		(Subscribed) share capital	Capital reserves	Legal reserves	Reserves for own shares	Own shares and interests (deductible item)	Statutory reserves	Other reserves	Revaluation reserves	Fair value of financial assets through other comprehensive income (available for sale)	Efficient part of cash flow protection	Efficient part of net investment abroad protection	Other fair value reserves	Exchange differences on translation of foreign operations	Profit/loss brought forward	Business year profit/loss	Total dividable among holders of parent company capital			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18 (3 do 6 - 7 + 8 do 17)	19	20 (18+19)	
PREVIOUS PERIOD																				
1	Status as at start of current business year	28	16,315,325	6,618,482	11,587,855	688,771	532,558	0	278,017	0	0	0	0	0	0	88,863,597	13,084,736	136,904,225	0	136,904,225
2	Accounting policies changes	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3	Error correction	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4	Status as at start of current business year (re-stated) (AOP 28 to 30)	31	16,315,325	6,618,482	11,587,855	688,771	532,558	0	278,017	0	0	0	0	0	0	88,863,597	13,084,736	136,904,225	0	136,904,225
5	Profit/loss period	32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10,362,355	10,362,355	0	10,362,355
6	Exchange differences on translation of foreign operations	33	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7	Changes in revaluation reserves of long-term tangible and intangible assets	34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8	Profit or loss based on subsequent valuation of financial assets toward fair value through other comprehensive income (available for sale)	35	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9	Profit or loss based on efficient cash flow protection	36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	Profit or loss based on efficient net abroad investment protection	37	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
11	Share in other comprehensive profit/loss of companies connected with participating interests	38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12	Actuarial gain/loss on defined benefit schemes	39	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
13	Other non-equity capital changes	40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
14	Transaction tax recognized directly in capital	41	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
15	Reduction of (subscribed) share capital (other than in pre-bankruptcy settlement proceedings and capital accrued through reinvesting profit)	42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16	Reduction of (subscribed) share capital in pre-bankruptcy settlement proceedings	43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17	17 Reduction of (subscribed) share capital accrued through reinvesting profit	44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
18	Purchase of own stocks/shares	45			0	-63,634	-63,635	0	0	0	0	0	0	0	0	504,332	0	504,333	0	504,333
19	Member/shareholder payments	46	274,352	1,899,994	0	0	0	0	0	0	0	0	0	0	0	0	0	2,174,346	0	2,174,346
20	Payment of share in profit/dividends	47	0	0	0	0	0	0	0	0	0	0	0	0	-4,960,232	0	-4,960,232	0	-4,960,232	
21	Other distributions and payments to members/shareholders	48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
22	Transfer according to yearly schedule	49	0	0	0	0	0	0	0	0	0	0	0	0	13,084,736	-13,084,736	0	0	0	
23	Increase of reserves in pre-bankruptcy settlement proceedings	50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
24	Status as at last day of reporting period for current business year (AOP 31 to 50)	51	16,589,677	8,518,476	11,587,855	625,137	468,923	0	278,017	0	0	0	0	0	0	97,492,433	10,362,355	144,985,027	0	144,985,027
ADDENDUM TO STATEMENT ON CHANGES IN EQUITY (filled out by undertaking IFRS payer)																				
I.	OTHER COMPREHENSIVE PROFIT FOR CURRENT PERIOD, REDUCED BY TAX (AOP 33 to 41)	52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
II.	COMPREHENSIVE PROFIT OR LOSS FOR CURRENT PERIOD (AOP 32+52)	53	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10,362,355	10,362,355	0	10,362,355
III.	TRANSACTIONS RELATING TO OWNERS FOR CURRENT PERIOD RECOGNIZED DIRECTLY IN CAPITAL (AOP 42 to 50)	54	274,352	1,899,994	0	-63,634	-63,635	0	0	0	0	0	0	0	0	8,628,836	-13,084,736	-2,281,553	0	-2,281,553

NOTES ACCOMPANYING FINANCIAL STATEMENTS – PFI

(created for the semi-annual period)

ISSUER NAME:	JGL d.d.
PIN (OIB):	20950636972
REPORTING PERIOD:	01.01.-30.06.2024.

Notes to financial statements for semi-annual periods include:

- a. explanation of business events relevant to understanding changes in the statement of financial position and financial performance for the reporting semi-annual period of the issuer with respect to the last business year: information is provided regarding these events and relevant information published in the last annual financial statement is updated (items 15 to 15C IAS 34 - Interim financial reporting)
All explanations are included in the Semi-annual management report.
- b. information on the access to the latest annual financial statements, for the purpose of understanding information published in the notes to financial statements drawn up for the semi-annual reporting period
The latest annual reports are available on the ZSE website and at <https://www.jgl.hr/o-jgl-u/fnancij-ski-izvjestaji>
- c. a statement explaining that the same accounting policies are applied while drawing up financial statements for the semi-annual reporting period as in the latest annual financial statements or, in the case where the accounting policies have changed, a description of the nature and effect of the changes (item 16.A (a) IAS 34 - Interim financial reporting)
The same accounting policies as for the annual financial statements for the year 2023 are applied for the preparation of these semi-annual reports.
- d. a description of the financial performance in the case of the issuer whose business is seasonal (items 37 and 38 IAS 34 - Interim financial reporting)
The group does not perform activities of a seasonal nature.
- e. other comments prescribed by IAS 34 - Interim financial reporting
- f. in the notes to the semi-annual financial state-

ments, in addition to the information stated above, information in respect of the following matters shall be disclosed:

1. undertaking's name, registered office (address), legal form, country of establishment, entity's registration number and, if applicable, the indication whether the undertaking is undergoing liquidation, bankruptcy proceedings, shortened termination proceedings or extraordinary administration
JGL d.d., Rijeka, Svilno 20., country of incorporation Croatia, other information can be found in the General Information sheet and in the Semi - annual management report.
2. adopted accounting policies (only an indication of whether there has been a change from the previous period)
There were no changes in accounting policies during 2024.
3. the total amount of any financial commitments, guarantees or contingencies that are not included in the balance sheet, and an indication of the nature and form of any valuable security which has been provided; any commitments concerning pensions of the undertaking within the group or company linked by virtue of participating interest shall be disclosed separately
This information is included in the Semi-annual management report.
4. the amount and nature of individual items of income or expenditure which are of exceptional size or incidence
Individual income items of exceptional size are explained in the Semi - annual management report. Items of exceptional size of expenditure are Direct costs of raw materials and materials amounting to EUR 23,151,193 or 22% of total expenditure, costs of purchase value of goods sold amounting to EUR 23,467,589 or 22% and staff costs amounting to EUR 18,409,665 or 17%.
5. amounts owed by the undertaking and falling due after more than five years, as well as the total debts of the undertaking covered by valuable security furnished by the undertaking, specifying the type and form of security
Of the total long-term liabilities in the amount of

EUR 68,201,723, liabilities with a term longer than 5 years account for EUR 27,416,799, namely leases EUR 504,925, loans EUR 26,144,804 and deferred tax liabilities in the amount of EUR 767,071.

1. average number of employees during the financial year
The average number of employees in the group in the period is 1310.
2. where, in accordance with the regulations, the undertaking capitalised on the cost of salaries in part or in full, information on the amount of the total cost of employees during the year broken down into the amount directly debiting the costs of the period and the amount capitalised on the value of the assets during the period, showing separately the total amount of net salaries and the amount of taxes, contributions from salaries and contributions on salaries
In the Profit and loss statement, salary expenses less capitalized amounts are shown, namely net salary in the amount of EUR 134,506, taxes and salary contributions in the amount of EUR 56,973 and salary contributions in the amount of EUR 25,669.
3. where a provision for deferred tax is recognised in the balance sheet, the deferred tax balances at the end of the financial year, and the movement in those balances during the financial year
In the observed period, deferred tax assets increased by EUR 552,309, while deferred tax liabilities increased by EUR 642,915.
4. the name and registered office of each of the undertakings in which the undertaking, either itself or through a person acting in their own name but on the undertaking's behalf, holds a participating interest, showing the proportion of the capital held, the amount of capital and reserves, and the profit or loss for the latest financial year of the undertaking concerned for which financial statements have been adopted; the information concerning capital and reserves and the profit or loss may be omitted where the undertaking concerned does not publish its balance sheet and is not controlled by another undertaking
In the Management Report, all members of the JGL Group are listed, and their ownership structure is described.
5. the number and the nominal value or, in the absence of a nominal value, the accounting par value of the shares subscribed during the financial year within the limits of the authorised capital
JGL d.d. increased the share capital by 21,104 new sha-

- res at a nominal value of EUR 13.00 on April 25, 2024.*
6. the existence of any participation certificates, convertible debentures, warrants, options or similar securities or rights, with an indication of their number and the rights they confer
There were no such participations or transactions.
the name, registered office and legal form of each of the undertakings of which the undertaking is a member having unlimited liability
7. the name, registered office and legal form of each of the undertakings of which the undertaking is a member having unlimited liability
JGL d.d. has unlimited responsibility in every company of the Group.
8. the name and registered office of the undertaking which draws up the consolidated financial statements of the largest group of undertakings of which the undertaking forms part as a controlled group member
JGL d.d. is the parent member of the group and is not a controlled member of any Group.
9. the name and registered office of the undertaking which draws up the consolidated financial statements of the smallest group of undertakings of which the undertaking forms part as a controlled group member and which is also included in the group of undertakings referred to in point 13
JGL d.d. is the only one that compiles a half-yearly consolidated report.
10. the place where copies of the consolidated financial statements referred to in points 13 and 14 may be obtained, provided that they are available
Not applicable.
11. the nature and business purpose of the undertaking's arrangements that are not included in the balance sheet and the financial impact on the undertaking of those arrangements, provided that the risks or benefits arising from such arrangements are material and in so far as the disclosure of such risks or benefits is necessary for the purposes of assessing the financial position of the undertaking
Not applicable.
12. the nature and the financial effect of material events arising after the balance sheet date which are not reflected in the profit and loss account or balance sheet
After the balance sheet date, the share capital was paid into the new subsidiary JADRAN Kazakhstan LLP, while ZU "Goranske ljekarna" was legally merged with ZU "Ljekarna Pablo". The financial effects are not significant.

STATEMENT OF RESPONSIBILITY OF THE CEO FOR THE PREPARATION AND APPROVAL OF THE SEMI-ANNUAL FINANCIAL REPORTS

In these materials, “JGL” or the “Company” means JADRAN – GALENSKI LABORATORIJ d.d. while “Group” means the Company and its subsidiaries.

According to the Accounting Act, the CEO is responsible for the preparation of financial statements that provide a true and fair view of the Group’s and the Company’s financial positions and business performance in accordance with the applied accounting policies, and for maintaining adequate accounting records that enable the preparation of such financial statements at any moment. The CEO has a general responsibility to undertake steps that would, to a reasonable extent, enable the protection of the Group’s and the Company’s assets and the discovery and prevention of fraud or other irregularities.

The CEO is responsible for selecting appropriate accounting policies in accordance with the applied accounting standards that should be applied consistently, for making reasonable and careful judgements and estimates, and for preparing financial statements in accordance with the going concern principle, unless the assumption that the Group or the Company will continue to operate is inappropriate.

The CEO has a reasonable expectation that the Group and the Company have the appropriate resources to continue operating in the foreseeable future. The CEO is responsible for submitting annual financial statements to the Company’s Board of Directors for their acceptance.

These statements represent consolidated statements of the Group and unconsolidated statements of the Company. The consolidated and the unconsolidated financial statements were approved by the CEO on 29th of August 2024 for submittal to the Company’s Board of Directors for their acceptance, as confirmed by his signature.



For JGL d.d.

Mislav Vučić
Chief Executive Officer

JGL d.d.
Svilno 20
51000 Rijeka

Graphic design
Studio Sudar

